{"index": 0, "picked_index": 1, "id": "6f132291-8a44-47a8-9979-1d359c074a7c", "question": "Nerve supply of the mucosa of larynx, from epiglottis to the level of the cords is :", "options": {"A": "Superior laryngeal", "B": "External laryngeal", "C": "External laryngeal and recurrent laryngeal", "D": "Internal laryngeal and recurrent laryngeal"}, "gold": "A", "subject_name": "Anatomy", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:35:48.862005+00:00", "branches": [{"branch": 0, "seed": 110042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "A", "is_correct": false, "inference_time_sec": 21.197614908218384, "model_output": "To determine the nerve supply of the mucosa of the larynx from the epiglottis to the level of the vocal cords, we need to consider the branches of the vagus nerve (cranial nerve X) that innervate the larynx.\n\n- The **superior laryngeal nerve** is a branch of the vagus nerve that divides into two branches: the internal laryngeal nerve and the external laryngeal nerve. The **internal laryngeal nerve** is responsible for the sensory innervation of the mucous membrane above the vocal cords, including the epiglottis and the aryepiglottic fold, up to the level of the vocal folds.\n\n- The **external laryngeal nerve** provides motor innervation to the cricothyroid muscle and sensory innervation to the mucosa of the larynx below the vocal cords. However, its sensory role is not the primary focus for the area from the epiglottis to the vocal cords.\n\n- The **recurrent laryngeal nerve** is also a branch of the vagus nerve and provides motor innervation to all the intrinsic muscles of the larynx except the cricothyroid. It also provides sensory innervation below the vocal folds, but it's not primarily responsible for the area from the epiglottis to the vocal cords.\n\nGiven this information, the nerve supply from the epiglottis to the level of the vocal cords is primarily sensory, which is the domain of the **internal laryngeal nerve**. The **recurrent laryngeal nerve** is involved in the area below the vocal folds. However, the question asks for the nerve supply from the epiglottis to the level of the vocal cords, which is more specifically associated with the **internal laryngeal nerve**. The external laryngeal nerve is not the primary choice for the mucosal innervation in this area, but it's included in the superior laryngeal nerve, which does innervate the area in question indirectly through its internal branch. Thus, the most accurate choice that includes the specific nerve responsible for the mucosal innervation from the epiglottis to the vocal cords, along with the broader context of the superior laryngeal nerve, would be the combination of the internal laryngeal and the superior laryngeal nerve, but since the question does not explicitly offer this combination, we consider the closest and most relevant option provided.\n\nSo, the correct answer, based on the information given and the typical anatomy, would involve the internal laryngeal nerve and considering the superior laryngeal nerve as a whole, but since that's not an option, we focus on the primary nerve for the area in question.\n\nThe final answer is D."}, {"branch": 1, "seed": 111039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 32.0659453868866, "model_output": "To determine the correct nerve supply for the mucosa of the larynx from the epiglottis to the level of the vocal cords, we need to consider the innervation provided by the branches of the vagus nerve (cranial nerve X).\n\nThe mucosa of the larynx, from the epiglottis down to the vocal cords, is primarily innervated by sensory fibers that arise from the internal laryngeal nerve. The internal laryngeal nerve is a branch of the superior laryngeal nerve, which in turn is a branch of the vagus nerve. The internal laryngeal nerve is responsible for the sensory innervation of the mucous membrane lining the larynx above the vocal cords, including the epiglottis.\n\nThe recurrent laryngeal nerves, also branches of the vagus nerve, provide motor innervation to all the intrinsic muscles of the larynx, including those that adjust the tension of the vocal cords. However, they do not provide sensory innervation to the mucosa above the vocal folds.\n\nThe external laryngeal nerve, another branch of the superior laryngeal nerve, provides motor innervation to the cricothyroid muscle, which is involved in stretching and tensing the vocal cords but does not innervate the mucosa.\n\nGiven this information, the correct choice for the nerve supply of the mucosa of the larynx from the epiglottis to the level of the vocal cords is the internal laryngeal nerve, which is part of the superior laryngeal nerve. However, since the question seems to imply a choice that involves a branch directly related to the internal laryngeal function in this area and the closest related option that includes this, we consider the broader category that includes both the superior laryngeal (for the internal laryngeal) and the specific involvement in the area around the larynx.\n\nSo, the correct answer, based on the options provided and focusing on the sensory innervation for the mucosa from the epiglottis to the level of the vocal cords, is the internal laryngeal and recurrent laryngeal nerves are not primarily responsible for the mucosal innervation in this specific area, but the option that includes the superior laryngeal nerve is most relevant. However, my detailed explanation might suggest a closer look at the direct involvement. The correct choice that directly matches the innervation pattern described should be the internal laryngeal, which is part of the superior laryngeal nerve. Yet, in the context of common clinical understanding and options provided:\n\n- A. Superior laryngeal is a branch that includes the internal laryngeal nerve but does not fully capture the relevant innervation on its own as described.\n- B. External laryngeal is not involved in mucosal innervation.\n- C. External laryngeal and recurrent laryngeal are not correct for the mucosal innervation in this area.\n- D. Internal laryngeal and recurrent laryngeal is the closest to the mucosal innervation pattern for the area described, considering the recurrent laryngeal's broader role in the larynx and the misunderstanding in the explanation provided.\n\nHowever, the accurate choice based on standard anatomical knowledge should emphasize the role of the internal laryngeal nerve, which is part of the superior laryngeal nerve. The correct choice reflecting this accurate innervation pattern should be:\n\nA. Superior laryngeal (as it encompasses the internal laryngeal nerve, which is the primary sensory nerve for the mucosa from the epiglottis to the vocal folds), but this direct selection isn't perfectly aligned with the provided options in the context of typical multiple-choice responses. For clarity and sticking strictly to the provided options and aiming for the most accurate reflection of the mucosal innervation in the described area, the closest and most appropriate interpretation would actually align with considering the superior laryngeal's role, but since that's not explicitly listed as a standalone option in a manner that perfectly matches the typical anatomical description, the selection process might seem slightly convoluted.\n\nGiven the clarification needed and sticking strictly to the format requested for a single, clear answer choice from the provided options, and acknowledging the confusion in the detailed explanation:\n\nThe final answer is A."}, {"branch": 2, "seed": 112036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "A", "is_correct": false, "inference_time_sec": 14.911647081375122, "model_output": "To determine the nerve supply of the mucosa of the larynx from the epiglottis to the level of the vocal cords, we need to understand the innervation of the larynx. The larynx is innervated by the vagus nerve (cranial nerve X) through its two branches: the internal laryngeal nerve and the recurrent laryngeal nerve.\n\n1. **Internal Laryngeal Nerve**: This branch of the superior laryngeal nerve (which itself is a branch of the vagus nerve) provides sensory innervation to the mucous membrane of the larynx above the vocal folds. This includes the area from the epiglottis down to the vocal folds, which is exactly the area in question.\n\n2. **Recurrent Laryngeal Nerve**: This also arises from the vagus nerve and supplies the muscles of the larynx, including those below the vocal folds, but it is primarily motor. However, it also provides sensory innervation to the mucosa below the vocal folds.\n\n3. **External Laryngeal Nerve**: This is a branch of the superior laryngeal nerve that supplies the cricothyroid muscle, which is involved in tensing the vocal cords. It does not provide sensory innervation to the mucosa of the larynx.\n\nGiven this information, the mucosa of the larynx from the epiglottis to the level of the vocal cords is innervated by the internal laryngeal nerve for the sensory supply, and the recurrent laryngeal nerve also plays a role in this region, particularly in the area below the vocal folds but does contribute to the innervation of the area in question.\n\nSo, the correct answer is the combination of the internal laryngeal and the recurrent laryngeal nerves, which together provide the sensory innervation to the mucosa of the larynx from the epiglottis to the level of the vocal cords.\n\nAnswer: D."}, {"branch": 3, "seed": 113033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "A", "is_correct": false, "inference_time_sec": 17.435081958770752, "model_output": "To determine the nerve supply of the mucosa of the larynx from the epiglottis to the level of the vocal cords, we need to consider the branches of the vagus nerve (cranial nerve X) that innervate the larynx.\n\nThe vagus nerve gives off several branches that provide sensory innervation to the larynx. The internal laryngeal nerve is a branch of the superior laryngeal nerve, which in turn is a branch of the vagus nerve. The internal laryngeal nerve is responsible for providing sensory innervation to the mucous membrane lining the larynx above the vocal folds, including the epiglottis, valleculae, and the area between the epiglottis and the vocal folds.\n\nThe recurrent laryngeal nerve, also a branch of the vagus nerve, provides sensory innervation to the mucosa of the larynx below the vocal folds, including the subglottis and the vocal folds themselves. However, it primarily innervates the intrinsic muscles of the larynx that control the tension and length of the vocal cords, which is not directly relevant to the mucosal innervation in question.\n\nGiven the options provided:\n\nA. Superior laryngeal - This option is incorrect because the superior laryngeal nerve itself is a branch of the vagus, but it is not the direct answer for the mucosal innervation below the level of the epiglottis.\n\nB. External laryngeal - This is incorrect because the external laryngeal nerve primarily innervates the cricothyroid muscle, one of the intrinsic muscles of the larynx, and not the mucosa.\n\nC. External laryngeal and recurrent laryngeal - This option is incorrect because the external laryngeal nerve does not innervate the mucosa, and while the recurrent laryngeal does, it's specifically below the level of the vocal folds.\n\nD. Internal laryngeal and recurrent laryngeal - This is the correct choice because the internal laryngeal nerve supplies the mucosa from the epiglottis to the vocal folds, and the recurrent laryngeal nerve supplies the mucosa from the vocal folds down, covering the entire area in question.\n\nSo, the answer is D."}, {"branch": 4, "seed": 114030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "A", "is_correct": false, "inference_time_sec": 18.41901659965515, "model_output": "To determine the correct nerve supply of the mucosa of the larynx from the epiglottis to the level of the vocal cords, let's analyze the options provided, considering the innervation of the larynx:\n\n1. **Superior Laryngeal Nerve (Option A):** The superior laryngeal nerve is a branch of the vagus nerve (cranial nerve X). It has an internal laryngeal branch that provides sensory innervation to the mucous membrane of the larynx above the vocal folds, including the epiglottis and the area between the epiglottis and the vocal cords. However, it does not innervate the area below the vocal folds.\n\n2. **External Laryngeal Nerve (Option B):** This nerve is also a branch of the superior laryngeal nerve, but it primarily supplies the cricothyroid muscle, which is involved in adjusting the tension of the vocal cords. It does not provide sensory innervation to the mucosa of the larynx.\n\n3. **External Laryngeal and Recurrent Laryngeal (Option C):** The recurrent laryngeal nerve, another branch of the vagus nerve, provides motor innervation to all the intrinsic muscles of the larynx except for the cricothyroid, which is innervated by the external laryngeal nerve. The recurrent laryngeal nerve also provides sensory innervation to the mucosa of the larynx below the vocal folds. However, the external laryngeal nerve does not contribute to the sensory innervation of the mucosa.\n\n4. **Internal Laryngeal and Recurrent Laryngeal (Option D):** The internal laryngeal nerve, a branch of the superior laryngeal nerve, provides sensory innervation to the mucosa of the larynx from the epiglottis down to the vocal folds. The recurrent laryngeal nerve, as mentioned, innervates the mucosa below the vocal folds. Together, they cover the entire area from the epiglottis down to the vocal folds.\n\nConsidering the areas innervated by the nerves mentioned, the correct answer is the combination of the internal laryngeal nerve, which covers the area from the epiglottis to the vocal folds, and the recurrent laryngeal nerve, which covers the area below the vocal folds.\n\nSo, the answer is D."}, {"branch": 5, "seed": 115027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "A", "is_correct": false, "inference_time_sec": 17.148192644119263, "model_output": "To determine the nerve supply of the mucosa of the larynx from the epiglottis to the level of the vocal cords, we need to consider the branches of the vagus nerve (cranial nerve X), which is primarily responsible for the innervation of the larynx.\n\n- The **superior laryngeal nerve** is a branch of the vagus nerve. It divides into two branches: the internal laryngeal nerve and the external laryngeal nerve. The **internal laryngeal nerve** provides sensory innervation to the mucosa of the larynx above the vocal cords, including the area from the epiglottis down to the vocal cords. It is responsible for the sensation in this area.\n\n- The **external laryngeal nerve** provides motor innervation to the cricothyroid muscle, which is involved in the tension of the vocal cords, but it does not supply the mucosal innervation below the level of the vocal cords.\n\n- The **recurrent laryngeal nerve** is also a branch of the vagus nerve. It supplies all the intrinsic muscles of the larynx below the vocal cords, except for the cricothyroid muscle. Importantly, it also provides sensory innervation to the mucosa below the vocal cords.\n\nGiven the options, to cover the mucosa from the epiglottis to the level of the vocal cords, we need a nerve that supplies both the sensory innervation above the vocal cords (which would be the internal laryngeal nerve) and the sensory innervation below the vocal cords (which would be the recurrent laryngeal nerve).\n\nOption A (Superior laryngeal) and Option B (External laryngeal) do not fully cover the area from the epiglottis to the level of the vocal cords because they do not account for the sensory innervation below the vocal cords. Option C (External laryngeal and recurrent laryngeal) is incorrect because the external laryngeal nerve does not provide mucosal innervation. Option D (Internal laryngeal and recurrent laryngeal) is the correct choice because it includes both the nerves responsible for the mucosal innervation from the epiglottis down to the vocal cords.\n\nSo, the answer is D."}, {"branch": 6, "seed": 116024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "A", "is_correct": false, "inference_time_sec": 16.547020196914673, "model_output": "To determine the correct answer, let's analyze the nerve supply of the larynx, specifically focusing on the mucosa from the epiglottis to the level of the vocal cords.\n\nThe larynx receives its nerve supply from branches of the vagus nerve (cranial nerve X). The vagus nerve divides into several branches that innervate different parts of the larynx:\n\n1. **Internal Laryngeal Nerve (ILN):** This is a branch of the superior laryngeal nerve (which in turn is a branch of the vagus nerve). The ILN provides sensory innervation to the mucosa of the larynx from the epiglottis down to the vocal folds. This includes the area between the epiglottis and the vocal cords.\n\n2. **Recurrent Laryngeal Nerve (RLN):** This nerve also originates from the vagus nerve and supplies the muscles of the larynx, except for the cricothyroid muscle, which is innervated by the external laryngeal nerve. The RLN provides motor innervation to the intrinsic muscles of the larynx, which control voice production, but it does not supply the mucosa.\n\n3. **External Laryngeal Nerve (ELN):** This is another branch of the superior laryngeal nerve and is primarily motor in function, innervating the cricothyroid muscle, which helps in adjusting the tension of the vocal cords. It does not innervate the mucosa of the larynx.\n\nGiven the information, the mucosa from the epiglottis to the level of the vocal cords is innervated by the internal laryngeal nerve, which is responsible for the sensory innervation in this area. The recurrent laryngeal nerve, while crucial for the motor innervation of the laryngeal muscles, does not supply the mucosa. Therefore, the correct answer involves the internal laryngeal nerve and does not include the external laryngeal nerve, which is only motor and does not supply the mucosa in question.\n\nSo, the correct answer is: **D. Internal laryngeal and recurrent laryngeal.**"}, {"branch": 7, "seed": 117021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "A", "is_correct": false, "inference_time_sec": 17.19663095474243, "model_output": "To determine the correct nerve supply of the mucosa of the larynx from the epiglottis to the level of the vocal cords, let's analyze the options provided, keeping in mind the innervation patterns of the larynx:\n\n1. **Superior Laryngeal Nerve (Option A):** The superior laryngeal nerve is a branch of the vagus nerve (cranial nerve X). It has an internal branch and an external branch. The internal branch of the superior laryngeal nerve is responsible for the sensory innervation of the mucous membrane above the vocal folds, including the epiglottis, valleculae, and the mucosa of the larynx up to the level of the vocal folds.\n\n2. **External Laryngeal Nerve (Option B):** This is another branch of the superior laryngeal nerve, but it provides motor innervation to the cricothyroid muscle, which is involved in tensing the vocal cords, not sensory innervation to the mucosa.\n\n3. **External Laryngeal and Recurrent Laryngeal Nerve (Option C):** The recurrent laryngeal nerve also branches from the vagus nerve but provides motor innervation to all the intrinsic muscles of the larynx except for the cricothyroid. However, it does not innervate the mucosa of the larynx from the epiglottis to the level of the vocal folds; it's more involved in the sensory and motor innervation below the vocal folds.\n\n4. **Internal Laryngeal and Recurrent Laryngeal (Option D):** The internal laryngeal nerve provides sensory innervation to the mucosa of the larynx from the level of the epiglottis down to the vocal folds. The recurrent laryngeal nerve, as mentioned, is more involved in motor functions and sensory innervation below the vocal folds, particularly the posterior part of the larynx.\n\nConsidering the above explanations, the correct answer is the option that includes the internal laryngeal nerve, which is responsible for the sensory innervation of the mucosa from the epiglottis to the level of the vocal cords.\n\nSo, the correct answer is D. Internal laryngeal and recurrent laryngeal."}, {"branch": 8, "seed": 118018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "A", "is_correct": false, "inference_time_sec": 16.785908699035645, "model_output": "To determine the correct answer, let's break down the innervation of the larynx, specifically focusing on the areas from the epiglottis to the level of the vocal cords.\n\n1. **Understanding the Laryngeal Nerves**: The larynx receives its nerve supply from the vagus nerve (cranial nerve X), which has two main branches that supply the larynx: the internal laryngeal nerve and the recurrent laryngeal nerve. The external laryngeal nerve, a branch of the superior laryngeal nerve, primarily supplies the cricothyroid muscle.\n\n2. **Internal Laryngeal Nerve**: This nerve is a branch of the superior laryngeal nerve, which itself is a branch of the vagus nerve. The internal laryngeal nerve provides sensory innervation to the mucosa of the larynx above the vocal cords, including the epiglottis. This area is crucial for the sensation of the upper part of the larynx.\n\n3. **Recurrent Laryngeal Nerve**: This nerve also branches from the vagus nerve but on the opposite side of the larynx from the internal laryngeal nerve. It supplies all the intrinsic muscles of the larynx (except for the cricothyroid muscle), including those involved in voice production, and provides sensory innervation to the mucosa below the vocal cords.\n\n4. **External Laryngeal Nerve**: This nerve is a branch of the superior laryngeal nerve and is primarily responsible for the motor innervation of the cricothyroid muscle, which adjusts the tension of the vocal cords. It does not provide sensory innervation to the mucosa.\n\nGiven this information, for the mucosa of the larynx from the epiglottis to the level of the vocal cords, the relevant nerves would be those providing sensory innervation. This area is specifically covered by the internal laryngeal nerve for the upper part (including the epiglottis) and the recurrent laryngeal nerve for the lower part, up to the vocal cords.\n\nSo, the correct answer involves both the internal laryngeal and the recurrent laryngeal nerves.\n\nThe final answer is D."}, {"branch": 9, "seed": 119015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "A", "is_correct": false, "inference_time_sec": 18.55480170249939, "model_output": "To determine the correct answer, let's break down the innervation of the larynx, specifically focusing on the mucosa from the epiglottis to the level of the vocal cords.\n\n1. **Understanding the Innervation**: The larynx receives its sensory innervation from the vagus nerve (cranial nerve X), which is crucial for the sensation of the laryngeal mucosa. The vagus nerve splits into two branches: the internal laryngeal nerve and the recurrent laryngeal nerve.\n\n2. **Internal Laryngeal Nerve**: This branch of the superior laryngeal nerve (which itself is a branch of the vagus nerve) provides sensory innervation to the mucous membrane of the larynx from the level of the epiglottis down to the vocal folds. This includes the area above the vocal folds, which is consistent with the area described in the question.\n\n3. **Recurrent Laryngeal Nerve**: This nerve also arises from the vagus nerve but has a different distribution. It provides motor innervation to all the intrinsic muscles of the larynx (except for the cricothyroid muscle, which is innervated by the external laryngeal nerve). Sensory innervation from the recurrent laryngeal nerve is below the vocal folds, affecting the subglottis.\n\n4. **External Laryngeal Nerve**: This nerve is a branch of the superior laryngeal nerve and provides motor innervation to the cricothyroid muscle, which is not directly related to the mucosal innervation described in the question.\n\nGiven the details above, the area from the epiglottis to the level of the vocal cords is specifically innervated by the internal laryngeal nerve, which is a branch of the superior laryngeal nerve, in conjunction with the recurrent laryngeal nerve for areas below the vocal folds, but since the question specifies up to the level of the vocal cords, the focus is on the internal laryngeal nerve. However, the recurrent laryngeal nerve is also crucial for the overall laryngeal innervation and should not be excluded in a comprehensive consideration of laryngeal innervation.\n\nTherefore, the most accurate answer, taking into account the comprehensive innervation and the specific area in question, would be the combination that includes both nerves involved in the sensory and motor aspects of laryngeal function up to the level of the vocal cords.\n\nThe final answer is D."}], "branch_preds": ["D", "A", "D", "D", "D", "D", "D", "D", "D", "D"], "metrics": {"leader": "D", "max_frac": 0.9, "variation_ratio": 0.09999999999999998, "entropy_bits": 0.4689955935892812, "valid_n": 10, "none_n": 0, "unanimous": false, "unanim_valid": false, "correct_fraction": 0.1, "leader_correct": false, "class": "lead80", "wall_time_sec": 190.290221452713, "mean_branch_time_sec": 19.02618601322174}}
{"index": 1, "picked_index": 2, "id": "3513f98e-19a9-4dfd-8f49-1e8514c3907c", "question": "In the formula for urea clearance, C = U x V/P, what does U stands for:", "options": {"A": "Urinary concentration in g/24 hour", "B": "Urinary concentration in mg/ml", "C": "Urine osmolarity", "D": "Urine volume per minute"}, "gold": "B", "subject_name": "Physiology", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:38:17.332785+00:00", "branches": [{"branch": 0, "seed": 210042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 15.282724618911743, "model_output": "To determine the correct answer, let's break down the formula for urea clearance, which is C = U x V/P, where C stands for clearance, U for the concentration of urea in the urine, V for the volume of urine produced per unit time, and P for the plasma concentration of urea.\n\n1. **Clearance (C)** is a measure of the volume of plasma from which urea is completely removed per unit time and is expressed in units like mL/min.\n\n2. **U (Urine concentration of urea)** represents the concentration of urea in the urine. This can be expressed in various units depending on the context, but in the context of clearance, it's often expressed in the same units as the plasma concentration, which is typically in mg/mL or mmol/L.\n\n3. **V (Volume of urine)** is the volume of urine produced per unit time, usually expressed in mL/min.\n\n4. **P (Plasma concentration)** is the concentration of urea in the plasma, also typically in mg/mL or mmol/L.\n\nGiven the options:\n- A. Urinary concentration in g/24 hour: This is not the typical unit for U in the clearance formula, especially when considering the units of the other components.\n- B. Urinary concentration in mg/ml: This is a plausible unit for U in the context of the formula, especially when the plasma concentration is also in mg/mL.\n- C. Urine osmolarity: Osmolarity is a measure of the concentration of osmotically active particles in a solution, which is not what U represents in the clearance formula.\n- D. Urine volume per minute: This is actually what V stands for, not U.\n\nTherefore, the correct answer is B, as U is the concentration of urea in the urine, and it is typically expressed in the same units as the plasma concentration for the formula to be dimensionally correct.\n\nSo, the correct formula when all units are in mg/mL would be: C (in mL/min) = (mg/mL urine) x (mL/min) / (mg/mL plasma)."}, {"branch": 1, "seed": 211039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 14.986982345581055, "model_output": "To determine the correct answer, let's break down the formula for urea clearance, which is C = U x V/P, where C stands for clearance, U for the concentration of the substance in the urine, V for the urine flow rate, and P for the plasma concentration of the substance.\n\n1. **U (Urine concentration):** In the context of the clearance formula, U represents the concentration of the substance (in this case, urea) in the urine. This concentration is typically expressed in the same units as the substance's plasma concentration. For urea, which is often measured in milligrams per deciliter (mg/dL), the urinary concentration would be in mg/dL as well.\n\n2. **V (Urine flow rate):** This is the volume of urine produced per unit of time, usually per minute, hour, or day. The specific time frame is often included in the units of the clearance (e.g., mL/min, mL/hour).\n\n3. **P (Plasma concentration):** This is the concentration of the substance in the plasma, also in the same units as U.\n\nGiven the options:\n- A. Urinary concentration in g/24 hour: This is not the typical unit for U in the clearance formula. While it's a measure of concentration, the use of grams and a 24-hour time frame doesn't fit the formula's context.\n- B. Urinary concentration in mg/ml: This is the correct unit for U in the context of the formula, as it matches the typical concentration units for substances like urea.\n- C. Urine osmolarity: Osmolarity is a measure of the concentration of osmotically active particles in a solution, not the concentration of a specific substance like urea.\n- D. Urine volume per minute: This is more accurately describing V (urine flow rate) rather than U.\n\nTherefore, the correct answer is the one that accurately represents the concentration of the substance (urea) in the urine in the context of the clearance formula.\n\nAnswer: B."}, {"branch": 2, "seed": 212036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 13.309753656387329, "model_output": "To determine the correct answer, let's break down the formula for urea clearance, which is C = U x V/P. \n\n1. **Understanding the formula components:**\n   - **C** represents urea clearance, which is the volume of plasma from which urea is completely removed per unit time (usually per minute or per hour).\n   - **U** stands for the concentration of urea in the urine. It's a measure of how much urea is present in the urine.\n   - **V** is the urine flow rate, or the volume of urine produced per unit time.\n   - **P** is the concentration of urea in the plasma, which is the concentration of urea in the blood.\n\n2. **Evaluating the options:**\n   - A. Urinary concentration in g/24 hour: This is not a measure of concentration in the formula but rather a measure over a period, which does not fit the formula's context of per unit time for clearance.\n   - B. Urinary concentration in mg/ml: This is the correct unit for U in the context of the formula. It measures how much urea is in the urine per milliliter, fitting the formula's requirement for concentration.\n   - C. Urine osmolarity: Osmolarity is a measure of the concentration of osmotically active particles in a solution, which is not directly what U represents in the clearance formula.\n   - D. Urine volume per minute: This would be more closely related to **V**, not **U**, as it refers to the volume of urine produced, not the concentration of urea in the urine.\n\nGiven the explanation, the correct answer is the one that represents the concentration of urea in the urine, which is necessary for calculating clearance rates accurately.\n\nSo, the answer is B."}, {"branch": 3, "seed": 213033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 13.579706192016602, "model_output": "To determine the correct answer, let's break down the formula for urea clearance, which is C = U x V/P. This formula is a part of the principles of renal physiology and is used to calculate the rate at which the kidneys clear a substance (in this case, urea) from the blood.\n\n- C represents the clearance of the substance (urea in this context), which is the volume of plasma from which the substance is completely removed per unit time.\n- U stands for the concentration of the substance in the urine.\n- V is the volume of urine produced per unit time (usually per minute).\n- P represents the plasma concentration of the substance.\n\nNow, let's analyze the options:\n\nA. Urinary concentration in g/24 hour: This is a measure of the amount of substance in the urine over a 24-hour period, not per unit of time that matches the V (which is typically in minutes or hours but is a volume, not a concentration).\n\nB. Urinary concentration in mg/ml: This is the correct interpretation of U in the formula. It represents the concentration of urea in the urine, typically measured in milligrams per milliliter (mg/ml).\n\nC. Urine osmolarity: Osmolarity is a measure of the concentration of osmotically active particles in a solution, expressed as the number of osmoles (or mOsm) of solute per kilogram of solvent. While related to concentration, it's not what U represents in the clearance formula.\n\nD. Urine volume per minute: This would be more closely related to V in the formula, not U. V is the volume of urine produced per unit time, which is used in conjunction with the concentration of the substance in the urine (U) to calculate the clearance.\n\nTherefore, the correct answer is B. Urinary concentration in mg/ml."}, {"branch": 4, "seed": 214030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 15.21904468536377, "model_output": "To solve this, let's break down the formula for urea clearance, which is indeed C = U x V/P. Understanding the components of this formula is key to identifying what U represents.\n\n1. **C** stands for clearance, which is a measure of the volume of plasma from which a substance is completely removed per unit time. In the context of the kidneys, it reflects the kidney's ability to remove waste, such as urea.\n\n2. **U** is the concentration of the substance in the urine. When calculating clearance, this is typically expressed as a concentration, which is usually in units of mg/dL or mmol/L for solutes like urea. The concentration in the urine reflects how much of the substance is being excreted per unit volume of urine.\n\n3. **V** stands for urine flow rate, which is the volume of urine produced per unit of time (e.g., per minute or per hour).\n\n4. **P** is the concentration of the substance in the plasma. This is the concentration of the substance being cleared from the blood.\n\nGiven these definitions:\n- **A. Urinary concentration in g/24 hour** is not the correct unit for U in this context, as U is usually a concentration and is often measured in smaller units like mg/dL.\n- **B. Urinary concentration in mg/ml** is the correct unit for U, as it reflects the concentration of the substance (like urea) in the urine.\n- **C. Urine osmolarity** is not what U represents; osmolarity is a measure of the concentration of osmotically active particles in a solution, which is different from the concentration of a specific substance like urea.\n- **D. Urine volume per minute** is what V represents, not U.\n\nSo, the correct answer is B, as U stands for the urinary concentration of the substance being cleared (in this case, urea), which is usually expressed in mg/ml or similar units when considering a 24-hour collection, it's more about concentration per unit volume rather than total grams.\n\nThe final answer is B."}, {"branch": 5, "seed": 215027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 12.163846492767334, "model_output": "To determine the correct answer, let's break down the formula for urea clearance, which is indeed C = U x V/P. \n\n- C stands for clearance, which is the volume of plasma from which the substance (in this case, urea) is completely removed per unit time.\n- U is the concentration of the substance in the urine, typically measured in units of mass per unit volume (e.g., mg/mL).\n- V is the urine flow rate, usually expressed in volume per unit time (e.g., mL/min).\n- P stands for the plasma concentration of the substance, also measured in the same units as U (e.g., mg/mL).\n\nGiven the options:\nA. Urinary concentration in g/24 hour - This option is incorrect because the units for 24-hour collection would not be appropriate for the formula which is typically used for clearance calculations that require per unit time (e.g., per minute or hour), but per minute is more standard for such calculations.\nB. Urinary concentration in mg/ml - This is the correct interpretation of U. It represents the concentration of urea in the urine, which is typically measured in milligrams per milliliter (mg/mL).\nC. Urine osmolarity - Osmolarity refers to the concentration of osmotically active particles in a solution, usually expressed in osmoles per liter (Osm/L). While related to concentration, it's not what U stands for in the clearance formula.\nD. Urine volume per minute - This is actually what V represents, not U. V is the urine flow rate, the volume of urine excreted per unit time.\n\nSo, the correct answer is B."}, {"branch": 6, "seed": 216024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 17.40378189086914, "model_output": "To determine the correct answer, let's break down the formula for urea clearance, which is C = U x V/P, and understand what each variable represents:\n\n- **C** stands for clearance, which is a measure of the rate at which a substance is removed from the blood by the kidneys. It's usually expressed in terms of volume of plasma cleared per unit time (e.g., mL/min).\n- **U** stands for the concentration of the substance in the **urine**. In the context of urea clearance, it refers to the concentration of urea in the urine. This concentration can indeed be expressed in various units, but the key is that it represents the amount of urea per unit volume of urine. The common units are often g/24 hour, mg/dL, or mmol/L, but since the formula is typically used in a more general form and involves a comparison with plasma, the focus is on the concentration aspect rather than the specific unit.\n- **V** stands for the volume of urine excreted per unit time, usually in the same units as the clearance (e.g., mL/min).\n- **P** stands for the plasma concentration of the substance, which in this case is urea. It is the concentration of urea in the blood.\n\nGiven the options provided:\nA. Urinary concentration in g/24 hour - This option is specific to a 24-hour period and does not directly match the usual context of the formula, which often considers rates over a minute or hour but does not specify a 24-hour period.\nB. Urinary concentration in mg/ml - This option directly refers to the concentration of a substance in urine, which aligns with the 'U' in the formula. The mg/ml unit is a common way to express concentration in the context of small volumes of fluid like urine.\nC. Urine osmolarity - Osmolarity refers to the concentration of osmotically active particles in a solution, measured in osmoles per liter (Osm/L). While related to concentration, this is not what 'U' stands for in the clearance formula.\nD. Urine volume per minute - This describes the 'V' in the formula, not the 'U'.\n\nTherefore, the correct answer is the one that represents the concentration of the substance (urea) in the urine, which is necessary for calculating clearance.\n\nThe final answer is B."}, {"branch": 7, "seed": 217021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 13.355569124221802, "model_output": "To determine the correct answer, let's break down the formula for urea clearance, which is indeed C = U x V/P.\n\n- **C** stands for clearance, which is a measure of the volume of plasma that is completely cleared of a substance per unit time.\n- **U** stands for the concentration of the substance in the urine, usually measured in units such as mg/dL (milligrams per deciliter), g/dL, or simply mg/mL when referring to the concentration of a substance in a unit volume of urine.\n- **V** stands for the urine flow rate, typically measured in milliliters per minute (mL/min) or liters per hour (L/hour), representing the volume of urine produced over a specific time period.\n- **P** stands for the plasma concentration of the substance, also measured in units such as mg/dL or g/dL, representing the concentration of the substance in the blood plasma.\n\nGiven the options:\n\nA. Urinary concentration in g/24 hour - This is not the correct unit for \"U\" in the context of the formula when considering typical clinical usage, as the formula often uses shorter time frames (e.g., minutes) for clearance calculations.\n\nB. Urinary concentration in mg/ml - This is the correct interpretation for \"U\" in the formula, as it represents the concentration of the substance (in this case, urea) in the urine.\n\nC. Urine osmolarity - Osmolarity refers to the concentration of osmotically active particles in a solution, measured in osmoles per liter (Osm/L). While related to urine concentration, it's not what \"U\" specifically represents in the clearance formula.\n\nD. Urine volume per minute - This is the correct definition for \"V\", not \"U\", in the formula for clearance.\n\nSo, the answer is B."}, {"branch": 8, "seed": 218018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 15.12870478630066, "model_output": "To determine the correct answer, let's break down the formula for urea clearance, which is C = U x V/P, and understand what each variable represents:\n\n- C stands for clearance, which is a measure of the volume of plasma from which a substance is completely removed per unit time by the kidneys.\n- U represents the concentration of the substance in the urine. Since we are discussing urea, U would be the concentration of urea in the urine.\n- V is the volume of urine produced per unit time, typically per minute or per hour, depending on how the clearance is calculated.\n- P represents the plasma concentration of the substance, in this case, urea.\n\nGiven the options provided:\nA. Urinary concentration in g/24 hour: This is not the correct unit for U in the context of the formula, as it's a 24-hour measurement and not directly applicable to the formula which usually calculates clearance per unit of time (like minutes or hours), but with a focus on per minute in the context of clearance rates.\nB. Urinary concentration in mg/ml: This is the correct unit for U in the formula. The concentration of urea in the urine is typically measured in mg/mL, which allows for the calculation of the volume of plasma from which urea is cleared per unit time.\nC. Urine osmolarity: Osmolarity is a measure of the concentration of osmotically active particles in a solution, expressed as the number of osmoles (mOsm) of solute per kilogram of solvent. It is not the same as the concentration of a specific substance like urea.\nD. Urine volume per minute: This describes V, not U, in the formula. V is the volume of urine produced per unit time, and it's the volume that, when multiplied by the concentration of the substance in the urine (U), gives the total amount of the substance excreted in the urine per unit time, divided by the plasma concentration (P) to find the clearance.\n\nTherefore, the correct answer is B. Urinary concentration in mg/ml."}, {"branch": 9, "seed": 219015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 18.002178192138672, "model_output": "To determine the correct answer, let's break down the formula for urea clearance, which is C = U x V/P, where C represents clearance, U represents the concentration of the substance in the urine, V is the urine flow rate (or urine volume), and P is the plasma concentration of the substance.\n\n1. **Understanding the formula components:**\n   - **C (Clearance):** This is the volume of plasma from which the substance is completely removed per unit time and is usually expressed in mL/min.\n   - **U (Urinary concentration):** This is the concentration of the substance in the urine, which can be expressed in various units depending on the substance. For urea, it's often given in terms of concentration (e.g., mg/dL for urea).\n   - **V (Urine volume):** This is the volume of urine excreted per unit time, typically in mL/min.\n   - **P (Plasma concentration):** This is the concentration of the substance in the plasma, also expressed in the same units as U.\n\n2. **Evaluating the options:**\n   - **A. Urinary concentration in g/24 hour:** This is not a suitable unit for the formula as it doesn't match the typical units for clearance (mL/min) or the usual way concentration is expressed in the formula (e.g., mg/dL).\n   - **B. Urinary concentration in mg/ml:** This is the most appropriate unit for U in the context of the formula. The concentration of a substance in the urine is often measured in milligrams per milliliter (mg/mL), which aligns with the formula's requirements for calculating clearance.\n   - **C. Urine osmolarity:** Osmolarity is a measure of the concentration of osmotically active particles in a solution, expressed in osmoles per liter (Osm/L). While it can relate to the concentration of substances in the urine, it is not what is directly used in the clearance formula for urea.\n   - **D. Urine volume per minute:** This is actually what V represents in the formula, not U. V is the urine flow rate, which is the volume of urine excreted per unit time, typically in mL/min.\n\n3. **Conclusion:** Based on the analysis, the correct answer is the option that refers to the concentration of the substance in the urine, which is used in the formula for calculating clearance.\n\nThe final answer is B."}], "branch_preds": ["B", "B", "B", "B", "B", "B", "B", "B", "B", "B"], "metrics": {"leader": "B", "max_frac": 1.0, "variation_ratio": 0.0, "entropy_bits": 0.0, "valid_n": 10, "none_n": 0, "unanimous": true, "unanim_valid": true, "correct_fraction": 1.0, "leader_correct": true, "class": "unanimous", "wall_time_sec": 148.45598125457764, "mean_branch_time_sec": 14.843229198455811}}
{"index": 2, "picked_index": 3, "id": "caec1fed-b5cf-4aa1-98bd-0c0806992f06", "question": "Which of the following hormones will be affected most after the change in sex hormone binding globulin?", "options": {"A": "Testosterone", "B": "Estrogen", "C": "Progesterone", "D": "DHEA"}, "gold": "A", "subject_name": "Physiology", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:40:36.338414+00:00", "branches": [{"branch": 0, "seed": 310042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 12.762051343917847, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that binds to sex hormones in the bloodstream, primarily testosterone and estrogen. It plays a crucial role in regulating the bioavailability of these hormones by transporting them to their target tissues. Changes in SHBG levels can significantly affect the levels of the hormones it binds to.\n\nA. Testosterone: Testosterone is a primary androgen, and a significant portion of it is bound to SHBG. Changes in SHBG levels can lead to changes in the amount of bioavailable testosterone, which can influence androgenic activity in the body.\n\nB. Estrogen: Estrogen levels can also be affected by SHBG, as a portion of estrogen is bound to SHBG. However, estrogen is primarily produced from the aromatization of testosterone in peripheral tissues, and its levels are more tightly regulated by other factors.\n\nC. Progesterone: Progesterone is a steroid hormone involved in the menstrual cycle and pregnancy. It is not significantly bound by SHBG; instead, it is transported in the bloodstream largely in a free form. Thus, changes in SHBG have a minimal effect on progesterone levels.\n\nD. DHEA (Dehydroepiandrosterone): DHEA is an androgenic steroid hormone produced by the adrenal glands. It is not significantly bound by SHBG. Instead, it is transported in the bloodstream mostly in a free form, and its levels are influenced by factors related to adrenal function rather than SHBG.\n\nConsidering the information above, the hormone most affected by a change in sex hormone-binding globulin would be testosterone, as a significant portion of it is bound to SHBG and changes in SHBG levels directly impact the amount of bioavailable testosterone.\n\nSo, the answer is A."}, {"branch": 1, "seed": 311039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 15.021928071975708, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that binds to sex hormones, including testosterone and estradiol (a form of estrogen), in the blood, making them unavailable for their biological effects. It primarily influences the levels of free (active) testosterone and estradiol, which are the fractions of these hormones that are not bound to proteins in the blood and are available to bind to their respective receptors in target tissues.\n\nA. Testosterone - SHBG binds to testosterone, reducing the amount of free testosterone available in the bloodstream. Changes in SHBG levels can significantly affect the levels of free testosterone, which is crucial for male reproductive and sexual health, as well as muscle mass and bone density.\n\nB. Estrogen - While SHBG does bind to estrogens, the effect of SHBG on estradiol (a form of estrogen) is less pronounced than on testosterone. Estradiol has a shorter half-life and is more tightly regulated by other mechanisms, such as the aromatization of androgens to estrogens in peripheral tissues.\n\nC. Progesterone - Progesterone is not significantly bound by SHBG. Its levels are more directly influenced by the hypothalamic-pituitary-ovarian axis in females and by the hypothalamic-pituitary-testicular axis in males, with LH (luteinizing hormone) playing a key role in stimulating its production.\n\nD. DHEA (Dehydroepiandrosterone) - DHEA is a precursor to both testosterone and estrogen, produced by the adrenal glands. While it is an androgen, its levels are not directly influenced by SHBG in the same way that testosterone and estradiol are. DHEA's levels are more directly regulated by the adrenal glands' response to ACTH (adrenocorticotropic hormone) from the pituitary gland.\n\nConsidering the role of SHBG, the hormone most affected by changes in its levels would be testosterone, as SHBG directly influences the amount of free (active) testosterone in the blood.\n\nAnswer: A."}, {"branch": 2, "seed": 312036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 11.27591586112976, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that binds to sex hormones in the blood, including testosterone and estradiol (a form of estrogen). Its primary role is to transport these hormones in the bloodstream and regulate their activity. \n\n- **Testosterone (Option A)** is a major androgen that is significantly bound by SHBG, approximately 60-70% of circulating testosterone is bound to SHBG. A change in SHBG levels would directly affect the amount of free testosterone available for its biological actions.\n\n- **Estrogen (Option B)**, specifically estradiol, is also bound by SHBG, but to a lesser extent than testosterone. A significant portion of estradiol is bound to albumin rather than SHBG.\n\n- **Progesterone (Option C)** is a steroid hormone that is primarily involved in the female menstrual cycle and pregnancy. It is not significantly bound by SHBG. Instead, it is mostly bound to albumin.\n\n- **DHEA (Dehydroepiandrosterone) (Option D)** is a weak androgen that is produced by the adrenal glands. While it is a sex hormone, it is not bound by SHBG to the same extent as testosterone and estrogen. It is more often bound to albumin and has a lower affinity for SHBG.\n\nGiven this information, the hormone that would be most affected by a change in sex hormone-binding globulin (SHBG) levels is testosterone, because it has the highest proportion of its circulation bound to SHBG.\n\nSo, the answer is A."}, {"branch": 3, "seed": 313033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 14.104296445846558, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that binds to sex hormones in the bloodstream, specifically testosterone and estrogen. It is primarily produced in the liver and binds to these hormones, transporting them in the bloodstream, and modulating their activity. \n\n- **Testosterone (A)** is a primary androgen hormone in males and an anabolic steroid that plays a key role in the development of male reproductive tissues and secondary sexual characteristics. Since testosterone has a high affinity for SHBG, changes in SHBG levels can significantly affect the amount of free (unbound) testosterone available in the bloodstream, which is the active form that can exert its effects on tissues.\n\n- **Estrogen (B)**, particularly estradiol, is the most potent form of estrogen in humans. While estrogen does bind to SHBG, the effect of changes in SHBG on free estrogen levels is less pronounced compared to testosterone because estradiol is less tightly bound to SHBG compared to testosterone.\n\n- **Progesterone (C)** is a steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. Progesterone is not typically bound to SHBG in the same way as testosterone and estrogen. It has a lower affinity for SHBG, and its transport in the bloodstream is less dependent on SHBG.\n\n- **DHEA (Dihydroepiandrosterone) (D)** is an androgenic steroid hormone produced in the adrenal glands. While DHEA can be converted to more potent androgens and estrogens, it is not directly bound to SHBG to the same extent as testosterone and estrogen.\n\nConsidering these points, the hormone most affected by a change in sex hormone-binding globulin (SHBG) levels would be testosterone, due to its high affinity for SHBG and the significant impact changes in SHBG levels can have on the availability of free (active) testosterone.\n\nSo, the answer is A."}, {"branch": 4, "seed": 314030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 14.136096715927124, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that binds to sex hormones, primarily testosterone and estradiol (a form of estrogen), in the blood. It transports these hormones, which are then released in a controlled manner. SHBG levels are influenced by various factors including genetics, age, body composition, and certain medical conditions. When SHBG levels change, the levels of the hormones that are bound to it also change, but the effect on the hormones is not uniform.\n\nA. Testosterone - Testosterone is significantly bound to SHBG. An increase in SHBG would result in more testosterone being bound, potentially leading to a decrease in the bioavailable (free) testosterone, which is the form that can exert its effects on the body. Conversely, a decrease in SHBG would increase the levels of free testosterone.\n\nB. Estrogen - Like testosterone, estrogen (specifically estradiol) is also bound to SHBG. Changes in SHBG would similarly affect the bioavailability of estradiol. However, the effect on estrogen's action might be less pronounced compared to testosterone because estrogen has more binding sites and a larger volume of distribution.\n\nC. Progesterone - Progesterone is not primarily bound to SHBG. It is more often associated with binding to other proteins such as albumin and corticosteroid-binding globulin. Therefore, changes in SHBG levels would have a minimal direct effect on progesterone levels.\n\nD. DHEA (Dehydroepiandrosterone) - DHEA is a precursor to sex hormones and is not significantly bound to SHBG. Its levels are more directly influenced by the adrenal glands and are not as directly affected by SHBG levels.\n\nConsidering these points, the hormone most directly and significantly affected by a change in SHBG levels would be testosterone, as it has a high binding affinity for SHBG and changes in SHBG can directly impact its bioavailability.\n\nAnswer: A."}, {"branch": 5, "seed": 315027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 13.69364070892334, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that transports sex hormones, including testosterone and estradiol (a form of estrogen), in the blood. It has a higher affinity for these hormones than they do for other proteins, which means it can bind to them and carry them in the bloodstream, thereby regulating their bioavailability and activity.\n\nA. Testosterone: Testosterone is one of the primary sex hormones that SHBG binds to. An increase or decrease in SHBG levels can lead to changes in the levels of free testosterone (the biologically active form of testosterone) in the blood. This, in turn, can affect various physiological processes, including muscle mass, bone density, and libido.\n\nB. Estrogen: Estrogen, particularly estradiol, is also bound by SHBG. However, estradiol has a higher affinity for albumin than for SHBG. While changes in SHBG can affect the levels of free estradiol, the impact is less pronounced compared to testosterone due to its higher affinity for albumin.\n\nC. Progesterone: Progesterone is another steroid hormone, but it is not primarily bound by SHBG. Instead, it is mainly bound to albumin. Therefore, changes in SHBG levels have a minimal effect on the levels of free progesterone.\n\nD. DHEA (Dehydroepiandrosterone): DHEA is a precursor to both testosterone and estrogen, produced by the adrenal glands. It is not primarily bound by SHBG but rather circulates in the free form. Thus, changes in SHBG levels do not significantly affect DHEA levels.\n\nConsidering the above information, the hormone most affected by a change in sex hormone-binding globulin (SHBG) would be testosterone, as SHBG has a significant binding capacity for testosterone, directly influencing its bioavailability and activity in the body.\n\nAnswer: A."}, {"branch": 6, "seed": 316024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 15.218335151672363, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that binds to sex hormones in the blood, primarily testosterone and estradiol (a form of estrogen), but to a lesser extent, also binds to androstenedione and dihydrotestosterone (DHT), as well as to a small extent, progesterone. However, the primary hormones it binds are testosterone and estradiol.\n\n1. **Testosterone**: SHBG has a high affinity for testosterone. It significantly binds to testosterone, which means that when SHBG levels change, it directly affects the levels of free (unbound) testosterone available in the bloodstream. An increase in SHBG can lead to a decrease in the amount of free testosterone, and a decrease in SHBG can lead to an increase in the amount of free testosterone.\n\n2. **Estrogen (Estradiol)**: Similar to testosterone, SHBG also binds estradiol. Changes in SHBG levels can affect the levels of free estradiol, influencing its activity in the body. However, the impact of SHBG on estradiol is somewhat less pronounced than on testosterone because estradiol is also produced in peripheral tissues and its levels are more tightly regulated.\n\n3. **Progesterone**: Progesterone has a lower affinity for SHBG compared to testosterone and estradiol. While SHBG can bind progesterone, the effect of changes in SHBG on progesterone levels is less significant compared to its effect on testosterone and estradiol.\n\n4. **DHEA (Dehydroepiandrosterone)**: DHEA is a precursor to sex hormones and does not have a high affinity for SHBG. The binding of DHEA by SHBG is minimal, so changes in SHBG levels have a minimal effect on DHEA.\n\nConsidering the above points, the hormone that will be most affected by a change in sex hormone-binding globulin (SHBG) levels is testosterone, due to its high affinity for SHBG and the significant impact changes in SHBG can have on its free levels.\n\nSo, the answer is A."}, {"branch": 7, "seed": 317021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 14.323691844940186, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that binds to sex hormones, including testosterone and estradiol (a form of estrogen), in the bloodstream. This binding has a few key effects: 1. **Reducing the amount of free hormone**: By binding to sex hormones, SHBG reduces the amount of free (unbound) hormone available for interaction with target cells. 2. **Regulating hormone transport and distribution**: It facilitates the transport of these hormones in the bloodstream and helps in their distribution to various tissues.\n\nNow, let's consider the options:\n\nA. **Testosterone**: Testosterone is significantly bound by SHBG. Changes in SHBG levels can directly affect the levels of bioavailable testosterone, as less SHBG means more free testosterone, and vice versa.\n\nB. **Estrogen**: Like testosterone, estradiol (a major form of estrogen) is also bound by SHBG. However, the effect of changes in SHBG on estrogen levels is similar to that on testosterone, but the physiological effects and clinical relevance might vary due to the different roles of testosterone and estrogen in the body.\n\nC. **Progesterone**: Progesterone is primarily not bound by SHBG. It is more bound by albumin, which is another plasma protein. Therefore, changes in SHBG levels have less direct impact on progesterone levels and activity.\n\nD. **DHEA (Dehydroepiandrosterone)**: DHEA is a precursor to androgens and estrogens and is not significantly bound by SHBG. Its metabolism and levels are more directly influenced by the activity of the adrenal glands and the enzyme 17,20-desmolase, rather than SHBG.\n\nGiven this information, the hormone most directly affected by changes in sex hormone-binding globulin (SHBG) would be testosterone, as it is significantly bound by SHBG and changes in SHBG levels directly influence the amount of free testosterone available.\n\nSo, the answer is A."}, {"branch": 8, "seed": 318018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 13.63091492652893, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that transports sex hormones, including testosterone and estradiol (a form of estrogen), in the blood. It binds to these hormones, modulating their bioavailability and activity. \n\nA. Testosterone: Testosterone is one of the primary hormones bound by SHBG. Changes in SHBG levels can significantly affect the levels of bioavailable testosterone in the body, as more or less testosterone would be available for tissues and cells when SHBG levels are altered.\n\nB. Estrogen: Estrogen, specifically estradiol, is also bound by SHBG. However, the impact of SHBG on estrogen levels is somewhat less pronounced compared to testosterone because estrogen has a higher affinity for other binding proteins, such as albumin, and because the body can convert androgens (like testosterone) into estrogens, thus indirectly influencing estrogen levels.\n\nC. Progesterone: Progesterone is primarily involved in the menstrual cycle and in maintaining the early stages of pregnancy. It is not bound by SHBG to the same extent as testosterone and estrogen. Progesterone's levels are more directly influenced by the corpus luteum and the placenta during pregnancy, rather than by SHBG.\n\nD. DHEA (Dehydroepiandrosterone): DHEA is an androgen produced by the adrenal glands. It is not bound by SHBG to a significant extent. DHEA serves as a precursor for the production of more potent androgens and estrogens in the body, but its levels are not directly influenced by SHBG.\n\nConsidering these points, the hormone most directly affected by changes in sex hormone-binding globulin (SHBG) would be testosterone, as it has a high affinity for SHBG and a significant portion of its bioavailability is dependent on SHBG levels.\n\nSo, the answer is A."}, {"branch": 9, "seed": 319015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 14.799596071243286, "model_output": "Sex hormone-binding globulin (SHBG) is a protein that binds to sex hormones, including testosterone and estradiol (a form of estrogen), in the blood. It transports these hormones and regulates their bioavailability. Changes in SHBG levels can significantly impact the levels of these hormones that are free and active in the body, as only a small fraction of the hormone is free (not bound to SHBG or other proteins), and this free fraction is biologically active.\n\n- **Testosterone (A)**: As testosterone is one of the primary sex hormones that SHBG binds to, changes in SHBG levels can significantly affect the levels of bioavailable testosterone. An increase in SHBG can lead to a decrease in free testosterone, and a decrease in SHBG can result in an increase in free testosterone.\n\n- **Estrogen (B)**: Estrogen, particularly estradiol, is also bound by SHBG. Changes in SHBG levels can affect the levels of estradiol that are available in the body. However, the primary source of estradiol in males is the aromatization of testosterone, so while SHBG affects estradiol levels, the impact is somewhat indirect through its influence on testosterone levels.\n\n- **Progesterone (C)**: Progesterone is not primarily bound by SHBG. It is more commonly bound to albumin. Therefore, changes in SHBG levels have a minimal direct effect on the levels of biologically active progesterone.\n\n- **DHEA (D)**: Dehydroepiandrosterone (DHEA) is a precursor to sex hormones and is not directly bound by SHBG. Its levels are more directly influenced by the adrenal glands and are not as significantly affected by SHBG levels as the other hormones listed.\n\nConsidering these points, the hormone most directly and significantly affected by changes in SHBG levels is testosterone, as it is the primary hormone bound by SHBG, and changes in SHBG can directly impact the levels of free (active) testosterone.\n\nSo, the answer is A."}], "branch_preds": ["A", "A", "A", "A", "A", "A", "A", "A", "A", "A"], "metrics": {"leader": "A", "max_frac": 1.0, "variation_ratio": 0.0, "entropy_bits": 0.0, "valid_n": 10, "none_n": 0, "unanimous": true, "unanim_valid": true, "correct_fraction": 1.0, "leader_correct": true, "class": "unanimous", "wall_time_sec": 138.98944067955017, "mean_branch_time_sec": 13.89664671421051}}
{"index": 3, "picked_index": 4, "id": "ddd74ca8-115f-444b-a754-28567fb618b1", "question": "Craniopagus is defined as fusion of:", "options": {"A": "Head and spine", "B": "Head only", "C": "Thorax and spine", "D": "Thorax only"}, "gold": "B", "subject_name": "Pediatrics", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:42:23.196588+00:00", "branches": [{"branch": 0, "seed": 410042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 8.296442031860352, "model_output": "To determine the correct answer, let's break down what each term means:\n\n- Craniopagus refers to a type of conjoined twinship where the twins are connected at the head. This term specifically indicates that the fusion is limited to the cranium (head).\n\nA. Head and spine - This option is incorrect because while craniopagus involves the head, it does not necessarily imply a connection to the spine. The term that might describe a fusion involving the head and spine would be more accurately described by another term.\n\nB. Head only - This option directly matches the definition of craniopagus, as it specifies a fusion that is limited to the heads of the twins.\n\nC. Thorax and spine - This option refers to a fusion involving the chest (thorax) and the spine, which is not the definition of craniopagus.\n\nD. Thorax only - This option is also incorrect as it refers to a fusion involving the chest, not the head.\n\nGiven the definitions, the correct answer is the one that aligns with the specific type of conjoined twins where the fusion is confined to the head.\n\nAnswer: B."}, {"branch": 1, "seed": 411039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "B", "is_correct": false, "inference_time_sec": 9.678878784179688, "model_output": "To answer this question, let's break down the definitions related to cranial and spinal fusions:\n\n1. **Craniopagus**: This term refers to a type of conjoined twinship where the twins are joined at the head. The prefix \"crani-\" comes from the Greek word for \"skull,\" indicating that the fusion involves the head. \n\n2. **Rachipagus**: This term refers to conjoined twins joined at the spine, using the Greek prefix \"rachis,\" meaning \"spine.\"\n\n3. **Thoracopagus**: This refers to conjoined twins joined at the chest (thorax).\n\nGiven these definitions:\n- **Option A (Head and spine)**: This would be more accurately described as craniorachischisis in the case of a severe neural tube defect, not a fusion of conjoined twins.\n- **Option B (Head only)**: This is the correct definition of craniopagus.\n- **Option C (Thorax and spine)**: This is the definition of thoracopagus.\n- **Option D (Thorax only)**: This would not describe a common type of conjoined twinship fusion but could relate to a different kind of congenital anomaly.\n\nTherefore, the correct answer is the one that accurately describes the fusion of heads in conjoined twins."}, {"branch": 2, "seed": 412036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 8.30824613571167, "model_output": "To answer this question, let's break down the term \"craniopagus\" and understand its meaning.\n\n- \"Crani-\" refers to the head or skull.\n- \"Pagus\" means joined or connected.\n\nGiven these roots, \"craniopagus\" specifically refers to a type of conjoined twin where the twins are connected at the head. This is the definition we need to match with the options provided.\n\nLet's evaluate the options:\nA. Head and spine - This option could be a description of a more complex conjoined twin scenario but does not specifically define craniopagus.\nB. Head only - This option aligns with the definition of craniopagus, as it specifies the fusion is limited to the head.\nC. Thorax and spine - This describes a fusion involving the chest and spine, which is not characteristic of craniopagus.\nD. Thorax only - This refers to the chest area, which does not match the definition of craniopagus.\n\nBased on the definition of \"craniopagus,\" the correct answer is the one that specifies the fusion is limited to the head.\n\nAnswer: B."}, {"branch": 3, "seed": 413033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 11.494421243667603, "model_output": "To answer this question, let's break down the definitions related to conjoined twins, which is what the term \"craniopagus\" pertains to:\n\n1. **Understanding Craniopagus**: The term \"craniopagus\" is a medical term used to describe a specific type of conjoined twinship. Conjoined twins are identical twins whose bodies are physically connected. The prefix \"crani-\" refers to the head, and \"pagus\" refers to a connection or joining. Therefore, craniopagus specifically indicates a connection involving the heads.\n\n2. **Analyzing the Options**:\n   - **A. Head and spine**: While conjoined twins can have various forms of fusion, craniopagus specifically refers to a fusion involving the head. However, it does not necessarily imply fusion with the spine.\n   - **B. Head only**: This option aligns with the definition of craniopagus, as it indicates a fusion that is specifically related to the heads of the twins.\n   - **C. Thorax and spine**: This option would describe a condition known as thoracopagus, where the fusion involves the thorax (chest area) and potentially the spine.\n   - **D. Thorax only**: This would not be a correct description of craniopagus but could relate to other forms of conjoined twins that involve the thorax.\n\n3. **Conclusion**: Based on the definition and understanding of the term \"craniopagus,\" the correct answer is the one that specifically involves the fusion of the heads of conjoined twins.\n\nAnswer: B."}, {"branch": 4, "seed": 414030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 12.003686904907227, "model_output": "To determine the correct answer, let's break down what each term means and relate it to the options provided:\n\n1. **Craniopagus**: The term \"craniopagus\" comes from the Greek words \"kranion,\" meaning skull, and \"pagos,\" meaning joined or fixed. In medical terminology, it specifically refers to a type of conjoined twin where the heads of the twins are joined together. This can vary in the extent of fusion, ranging from a partial to a complete fusion of the skulls.\n\n2. **Analysis of Options**:\n   - **A. Head and spine**: This option suggests a fusion that includes both the head and the spine, which is not specific to craniopagus. This condition is more akin to rachischisis, a rare congenital disorder where there is an incomplete closing of the backbone and membranes covering the spinal cord.\n   - **B. Head only**: This option aligns with the definition of craniopagus, as it specifically involves the fusion of the heads of conjoined twins.\n   - **C. Thorax and spine**: This would refer to a thoracopagus, another type of conjoined twin, where the upper body, including the thorax (chest) and sometimes the spine, are joined.\n   - **D. Thorax only**: This would refer to a thoracopagus as well, but limited to a fusion involving only the thorax, which does not match the definition of craniopagus.\n\nBased on the above analysis, the correct definition of craniopagus is the fusion of the heads of conjoined twins.\n\nAnswer: B."}, {"branch": 5, "seed": 415027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "B", "is_correct": false, "inference_time_sec": 15.392100095748901, "model_output": "To answer this question, let's break down the definitions related to cranial and thoracic conjoined twins, which are types of conjoined twins that share a part of their bodies.\n\n1. **Cranium (Crani-):** The term \"cranium\" refers to the upper part of the skull that encloses the brain. In medical terminology, when a condition involves the cranium, it usually pertains to the head or the skull.\n\n2. **Conjoined Twins and Fusion Types:**\n   - **Craniopagus:** This term specifically refers to conjoined twins where the fusion occurs at the head. It's one of the most complex forms of conjoined twinning and involves a partial or complete fusion of the skulls of the two twins.\n   - **Rachipagus:** This term is used for conjoined twins whose fusion involves the spine or the spinal column.\n   - **Thoracopagus:** This refers to conjoined twins whose fusion occurs at the chest or thorax.\n   - **Omphalopagus:** This term is used when the conjoined twins are joined at the abdomen, specifically at the navel or omphalos area.\n\nGiven these definitions:\n- **Option A (Head and spine):** This describes a fusion involving the cranium and the spine, which would be more accurately described as rachipagus, not craniopagus.\n- **Option B (Head only):** This is the correct definition of craniopagus, as it involves the fusion of the heads or skulls of conjoined twins.\n- **Option C (Thorax and spine):** This describes a thoracopagus, not craniopagus, as it involves the chest and spine.\n- **Option D (Thorax only):** This would be a thoracopagus, not craniopagus, as it refers to a fusion involving the thorax.\n\nSo, the correct answer is the one that aligns with the definition of craniopagus, which involves the fusion of the heads of conjoined twins."}, {"branch": 6, "seed": 416024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "B", "is_correct": false, "inference_time_sec": 10.254774570465088, "model_output": "To determine the correct answer, let's break down the definition of craniopagus and the other options provided:\n\n- **Craniopagus** refers to a type of conjoined twinship where the twins are physically connected at the head. This condition occurs when the twins' skulls (crania) fuse together during fetal development. It is a rare form of conjoined twinning, which is itself a rare occurrence, accounting for about 1 in every 200,000 births.\n\nNow, let's evaluate the options:\nA. Head and spine - This option does not accurately describe craniopagus, as craniopagus specifically involves the fusion of heads, not the head and spine.\nB. Head only - This is the correct definition of craniopagus. It involves the fusion of the heads of conjoined twins.\nC. Thorax and spine - This describes a different form of conjoined twinning, not craniopagus. The fusion at the thorax (chest) and spine would be classified as thoracopagus or another specific type of thoraco-somatic fusion, not craniopagus.\nD. Thorax only - This option is incorrect as it refers to a different part of the body and does not describe craniopagus.\n\nGiven the information, the correct answer is the one that accurately describes the fusion of the heads of conjoined twins."}, {"branch": 7, "seed": 417021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 9.344745635986328, "model_output": "To answer this question, let's break down the term \"craniopagus\" and understand what it refers to in medical terminology.\n\n- \"Crani-\" comes from the Greek word for skull or head.\n- \"Pagus\" is a Latin word that means joined or united.\n\nGiven this etymology, \"craniopagus\" would literally translate to something related to the joining or fusion of skulls or the head.\n\nLet's examine the options:\n\nA. Head and spine: This option involves the fusion of the head with the spine, which does not match the specific meaning of \"craniopagus\" since it includes the spine, not just the head.\n\nB. Head only: This option aligns perfectly with the definition of \"craniopagus,\" as it involves the fusion of skulls or parts of the head.\n\nC. Thorax and spine: This option involves the chest (thorax) and the spine, which is not related to the definition of \"craniopagus.\"\n\nD. Thorax only: This option is also unrelated to the definition, as it involves the thorax, not the head.\n\nConsidering the meaning of \"craniopagus,\" the correct answer is clearly related to the fusion of the head.\n\nSo, the answer is B."}, {"branch": 8, "seed": 418018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 10.009493112564087, "model_output": "To answer this question, let's break down the definitions related to congenital disorders involving the fusion of parts of the body:\n\n1. **Craniopagus**: This term refers to a rare form of conjoined twins where the twins are physically connected at the head. The prefix \"crani-\" means \"relating to the skull,\" and \"pagus\" means \"joined at birth.\" This condition specifically involves the fusion of the skulls of two fetuses that have not fully separated during development.\n\n2. **Other Options**:\n   - **A. Head and spine**: This option is misleading because while conjoined twins can be connected at various parts of the body, the term craniopagus specifically refers to head-to-head fusion, not head-to-spine fusion, which would be a different type of conjoinment.\n   - **C. Thorax and spine**: This would refer to a condition where the twins are joined at the chest (thorax) and possibly the spine, which is not related to craniopagus.\n   - **D. Thorax only**: This option is unrelated to craniopagus as it specifically mentions the thorax (chest area) and does not involve the head.\n\nGiven the definitions, the correct answer is the one that specifically involves the fusion of the heads of conjoined twins.\n\nSo, the answer is B. Head only."}, {"branch": 9, "seed": 419015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "B", "gold": "B", "is_correct": true, "inference_time_sec": 12.023856163024902, "model_output": "To answer this question, let's break down the terms related to conjoined twins, which is what \"craniopagus\" refers to:\n\n- **Conjoined twins** are identical twins who are physically connected at some point during fetal development. The type of connection can vary, and the terms are often descriptive of the areas of the body that are fused.\n\n- **Craniopagus** specifically refers to a type of conjoinment where the twins are joined at the head. This term is derived from \"cranium,\" meaning skull, indicating the area of fusion.\n\n- **Craniopagus parasiticus** is a rare form where one twin's head is completely dependent on the other for survival, often with the smaller head being non-viable. In contrast, **craniopagus diprosopus** refers to a more complex form where the twins share a head but have separate trunks.\n\nNow, considering the options provided:\nA. Head and spine - This is not specific enough, as some forms of conjoinment involve the spine but are not classified under craniopagus.\nB. Head only - This accurately describes craniopagus, as it specifically refers to the fusion of twins at the head.\nC. Thorax and spine - This describes thoracopagus, a type of conjoinment where twins are joined at the chest and possibly the spine.\nD. Thorax only - This would refer to a different type of conjoinment not classified as craniopagus.\n\nGiven the definitions, the correct answer is the one that specifies the fusion of the head only, which is characteristic of craniopagus.\n\nAnswer: B."}], "branch_preds": ["B", "C", "B", "B", "B", "C", "C", "B", "B", "B"], "metrics": {"leader": "B", "max_frac": 0.7, "variation_ratio": 0.30000000000000004, "entropy_bits": 0.8812908992306927, "valid_n": 10, "none_n": 0, "unanimous": false, "unanim_valid": false, "correct_fraction": 0.7, "leader_correct": true, "class": "lead50", "wall_time_sec": 106.82937979698181, "mean_branch_time_sec": 10.680664467811585}}
{"index": 4, "picked_index": 5, "id": "d8a284c5-175a-4439-8ef2-5ff24b41f3cc", "question": "A 30 year old female is on antibiotics with prolonged IV cannulation, has spike of fever, the likely cause is :", "options": {"A": "Pseudomonas aerugenosa", "B": "Coagulase negative staphylococcus", "C": "Streptococcus agalactiae", "D": "E. coli"}, "gold": "B", "subject_name": "Microbiology", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:44:59.757264+00:00", "branches": [{"branch": 0, "seed": 510042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 13.363322257995605, "model_output": "When considering a 30-year-old female on antibiotics with prolonged IV cannulation who develops a spike of fever, we need to consider the common causes of nosocomial (hospital-acquired) infections, particularly those related to central line-associated bloodstream infections (CLABSIs). Prolonged IV cannulation increases the risk of such infections due to the entry point for bacteria into the bloodstream.\n\nA. Pseudomonas aeruginosa: This bacterium is known for causing infections in immunocompromised patients, those with cystic fibrosis, and in the context of hospital-acquired infections, especially in patients with prolonged IV access. It is a common cause of CLABSIs, particularly in patients with long-term catheters.\n\nB. Coagulase-negative staphylococcus (CoNS), particularly Staphylococcus epidermidis, is also a cause of catheter-related bloodstream infections. However, it is more commonly associated with short-term catheter use and is less likely to cause a \"spike\" of fever unless the patient is severely immunocompromised or has a long-standing catheter.\n\nC. Streptococcus agalactiae (Group B Streptococcus) is a common cause of infections in newborns and pregnant women but is less commonly associated with IV cannulation-related infections in otherwise healthy adults.\n\nD. E. coli is a common cause of urinary tract infections and can cause bloodstream infections, but it is not typically associated with IV cannulation in the context of CLABSIs compared to the other options.\n\nGiven the context of prolonged IV cannulation and a \"spike of fever,\" the most likely cause is an organism known for causing infections in this setting, which points towards Pseudomonas aeruginosa, especially in a healthcare-associated setting.\n\nSo, the answer is A."}, {"branch": 1, "seed": 511039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 13.224593877792358, "model_output": "When a patient, particularly one with a compromised immune system due to prolonged IV cannulation and antibiotic use, develops a fever, we must consider infections that are commonly associated with these risk factors. Here's a breakdown of the options:\n\nA. Pseudomonas aeruginosa: This bacterium is known for its ability to thrive in moist environments and is a common cause of hospital-acquired infections, particularly in patients with compromised skin integrity, such as those with prolonged IV cannulation. It is also notorious for its resistance to many antibiotics, which makes it a significant concern in healthcare settings.\n\nB. Coagulase-negative staphylococcus (CoNS): While CoNS, particularly Staphylococcus epidermidis, can cause infections related to indwelling medical devices like IV lines, it is more commonly associated with colonization rather than causing a significant infection like a spike in fever, especially in a previously healthy individual.\n\nC. Streptococcus agalactiae (Group B Streptococcus): This bacterium is more commonly associated with infections in newborns, pregnant women, and the elderly. It's less commonly associated with IV cannulation-related infections in otherwise healthy adults.\n\nD. E. coli: Escherichia coli (E. coli) can cause a variety of infections, but it is more commonly associated with urinary tract infections, gastrointestinal infections, and, in some cases, bloodstream infections, but it is less commonly associated with IV cannulation-related infections compared to Pseudomonas aeruginosa.\n\nGiven the context of prolonged IV cannulation and the presence of fever, the most likely cause is a bacterium known for its association with such invasive medical devices and its ability to cause severe infections in the hospital setting.\n\nSo, the answer is A. Pseudomonas aeruginosa."}, {"branch": 2, "seed": 512036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 17.85964012145996, "model_output": "To approach this question, let's consider the key details provided and analyze each option in the context of the clinical scenario:\n\n1. **Prolonged IV cannulation**: This is a significant risk factor for infection, particularly with organisms that are known to colonize the skin or thrive in moist environments. Prolonged use of IV lines can lead to the introduction of bacteria into the bloodstream.\n\n2. **Spike of fever**: This indicates a likely infectious process, as fever is a common systemic response to infection.\n\nNow, let's evaluate the options:\n\nA. **Pseudomonas aeruginosa**: This bacterium is known for causing infections in immunocompromised patients and those with breaches in the skin or mucosal barriers, such as those with prolonged IV cannulation. Pseudomonas is a common cause of hospital-acquired infections, particularly in patients with long-term indwelling catheters or IV lines. It is also known for its resistance to many antibiotics, making it a serious concern.\n\nB. **Coagulase-negative staphylococcus (CoNS)**: While CoNS, particularly Staphylococcus epidermidis, can cause infections related to indwelling devices, it is more commonly associated with device-related infections rather than causing systemic infections that present with a high fever unless the infection is severe or has disseminated.\n\nC. **Streptococcus agalactiae (Group B Streptococcus)**: This bacterium can cause severe infections, especially in neonates, pregnant women, and the elderly, but it is less commonly associated with IV device-related infections in otherwise healthy adults.\n\nD. **E. coli**: While E. coli can cause urinary tract infections and is a common cause of bloodstream infections, it is less commonly associated with infections related to IV cannulation compared to Pseudomonas aeruginosa.\n\nGiven the clinical scenario of a 30-year-old female with a spike of fever and prolonged IV cannulation, the most likely cause is an organism that is commonly associated with device-related infections, particularly in a hospital setting and in the presence of immunocompromising conditions or breaches in the skin barrier.\n\nTherefore, **Pseudomonas aeruginosa** (Option A) is the most likely cause due to its propensity for causing infections in patients with indwelling devices and its association with hospital-acquired infections, especially in the context of prolonged IV cannulation.\n\nAnswer: A."}, {"branch": 3, "seed": 513033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 15.780147790908813, "model_output": "To approach this question, let's consider the key points provided:\n\n1. **Patient Profile**: A 30-year-old female on prolonged IV cannulation.\n2. **Clinical Presentation**: Spike of fever.\n\n**Prolonged IV cannulation** is a significant risk factor for catheter-related bloodstream infections (CRBSIs). The most common pathogens responsible for these infections can be categorized based on the type of pathogen and the setting. Here's a brief overview of the options provided:\n\n- **A. Pseudomonas aeruginosa**: This bacterium is known for causing infections in healthcare settings, particularly in patients with prolonged hospital stays or those with compromised immune systems. It is a common cause of CRBSIs, especially in patients with long-term IV catheters. Pseudomonas aeruginosa is known for its resistance to many antibiotics, making infections challenging to treat.\n\n- **B. Coagulase-negative staphylococcus (CoNS)**: While CoNS, particularly Staphylococcus epidermidis, is a common cause of CRBSIs, it is more commonly associated with short-term intravascular catheters and less commonly with prolonged cannulation. However, it's still a possibility.\n\n- **C. Streptococcus agalactiae (Group B streptococcus)**: This bacterium is more commonly associated with infections in newborns and pregnant women, and less frequently with CRBSIs in adults, especially not typically associated with prolonged IV cannulation.\n\n- **D. E. coli**: While E. coli can cause bloodstream infections, it is less commonly associated with CRBSIs compared to the other pathogens listed. E. coli infections are more often associated with urinary tract infections or gastrointestinal infections.\n\nGiven the specific context of prolonged IV cannulation and a spike of fever, the most likely cause is a pathogen that is known to thrive in the hospital environment, particularly in devices such as IV catheters, and is known to cause serious infections in such settings. **Pseudomonas aeruginosa** fits this description well, making it the most likely cause of the fever spike in this scenario.\n\n**Answer: A.**"}, {"branch": 4, "seed": 514030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 15.174239158630371, "model_output": "To approach this question, let's consider the clinical scenario and the typical pathogens associated with specific clinical contexts:\n\n1. **Prolonged IV cannulation**: This is a significant risk factor for infections, particularly those caused by bacteria that thrive in moist environments or on the skin. The skin is a natural barrier, and breaches, such as those caused by IV cannulation, can lead to infections.\n\n2. **Spike of fever**: This indicates a possible acute infection. The type of bacteria involved can often be inferred by the clinical context, including the site of infection and any predisposing factors.\n\n3. **Common pathogens in IV line infections**:\n   - **Pseudomonas aeruginosa (A)**: This bacterium is known for its association with hospital-acquired infections, particularly in patients with prolonged IV cannulation or those with compromised immune systems. It thrives in moist environments and can form biofilms, making it difficult to eradicate.\n   - **Coagulase-negative staphylococcus (B)**, such as Staphylococcus epidermidis, is also a common cause of catheter-related bloodstream infections. However, it's more commonly associated with indwelling catheters, especially central lines, rather than peripheral lines.\n   - **Streptococcus agalactiae (C)**, also known as Group B Streptococcus, is more commonly associated with infections in newborns, pregnant women, and the elderly. It's less commonly associated with IV cannulation infections in healthy adults.\n   - **E. coli (D)**: While E. coli can cause a variety of infections, it's more commonly associated with urinary tract infections, gastrointestinal infections, or infections related to the genitourinary tract rather than IV cannulation.\n\nConsidering the information above, **Pseudomonas aeruginosa** is the most likely cause of a fever spike in a patient with prolonged IV cannulation due to its known association with hospital-acquired infections in patients with breaches in the skin barrier, such as IV sites.\n\nSo, the answer is A."}, {"branch": 5, "seed": 515027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 16.214585781097412, "model_output": "To approach this question, let's consider the clinical scenario and the common pathogens associated with specific risk factors and clinical presentations:\n\n1. **Prolonged IV cannulation**: This is a key risk factor for certain types of infections. Central line-associated bloodstream infections (CLABSIs) are a significant concern, particularly when intravenous lines are in place for extended periods. These infections can be caused by a variety of bacteria, but some are more commonly associated with this type of invasive device.\n\n2. **Spike of fever**: This indicates a possible infection or sepsis. Fever is a non-specific symptom but, in the context of IV cannulation, it strongly suggests an infection related to the catheter.\n\n3. **Common pathogens in this scenario**:\n   - **A. Pseudomonas aeruginosa**: This bacterium is known for its association with hospital-acquired infections, particularly in patients with prolonged exposure to medical devices, such as IV lines. It is known for its resistance to many antibiotics and is a common cause of CLABSIs.\n   - **B. Coagulase-negative staphylococcus (CoNS)**: While CoNS, especially Staphylococcus epidermidis, is a common cause of catheter-related infections, it's more commonly associated with less severe infections, like exit site infections or tunnel infections, rather than a spike in fever indicating bacteremia.\n   - **C. Streptococcus agalactiae (Group B Streptococcus)**: This is a common cause of neonatal infections and, in adults, can cause infections like pneumonia, meningitis, or bacteremia, but it's less commonly associated with IV device-related infections compared to Pseudomonas.\n   - **D. E. coli**: While E. coli can cause a wide range of infections, including urinary tract infections and bacteremia, it's not as specifically associated with IV cannulation and CLABSIs as Pseudomonas aeruginosa.\n\nGiven the information and focusing on the risk associated with prolonged IV cannulation and the clinical presentation of a fever spike, the most likely cause is a pathogen commonly linked to central line-associated infections.\n\nSo, the answer is A."}, {"branch": 6, "seed": 516024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 15.075023651123047, "model_output": "When a patient is on prolonged IV cannulation and experiences a spike of fever, the primary concern is a hospital-acquired infection, particularly a catheter-related bloodstream infection (CRBSI). Each of the options provided is a potential pathogen, but the likelihood varies based on the clinical context and the nature of the infection.\n\nA. Pseudomonas aeruginosa: This bacterium is a common cause of infections in healthcare settings, particularly in patients with compromised immune systems or with medical devices like IV catheters. It is known for its ability to colonize and infect via breaches in the skin, and it thrives in moist environments, making it a likely candidate for catheter-related infections.\n\nB. Coagulase-negative staphylococcus (CoNS): While CoNS, particularly Staphylococcus epidermidis, is a common skin commensal and can cause infections related to medical devices, it is more commonly associated with biofilm formation on prosthetic devices rather than causing a sudden spike in fever. It's a common cause of CRBSI but often presents with a more indolent course.\n\nC. Streptococcus agalactiae (Group B Streptococcus): This bacterium is more commonly associated with infections in pregnant women, newborns, and in some cases, in the elderly or immunocompromised. It is less commonly associated with catheter-related infections in otherwise healthy adults.\n\nD. E. coli: Escherichia coli (E. coli) can cause a wide range of infections, including urinary tract infections and sepsis. However, it is less commonly associated with catheter-related bloodstream infections compared to Pseudomonas aeruginosa, especially in the context of a prolonged IV cannulation.\n\nGiven the scenario of a 30-year-old female on prolonged IV cannulation with a spike of fever, the most likely cause among the options provided, due to its virulence, ability to cause severe infections in healthcare settings, and its common association with catheter-related infections, is Pseudomonas aeruginosa.\n\nSo, the answer is A."}, {"branch": 7, "seed": 517021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 15.359565496444702, "model_output": "To approach this question, let's consider the key points provided:\n\n1. **Prolonged IV cannulation**: This is a significant risk factor for introducing bacteria into the bloodstream, leading to a condition known as central line-associated bloodstream infections (CLABSIs). Certain organisms are more commonly associated with these infections due to their virulence and ability to adhere to and colonize catheters.\n\n2. **Spike of fever**: This indicates a systemic infection, which could be due to a variety of causes, including bacteria, viruses, or fungi. However, when considering the context of IV cannulation, we focus on bacterial causes.\n\n3. **Common pathogens in IV line infections**: \n   - **Pseudomonas aeruginosa (A)**: This is a common cause of hospital-acquired infections, particularly in patients with compromised immune systems or those with devices like IV lines. It is known for its resistance to many antibiotics and its ability to form biofilms on catheters.\n   - **Coagulase-negative staphylococcus (B)**, especially Staphylococcus epidermidis, is a frequent cause of catheter-related bloodstream infections. It is a part of the normal skin flora and can easily colonize medical devices.\n   - **Streptococcus agalactiae (C)**, also known as Group B streptococcus, is more commonly associated with infections in newborns, pregnant women, and can cause various infections in adults, but it is less commonly linked to IV line infections.\n   - **E. coli (D)**: While E. coli can cause a variety of infections, including urinary tract infections and sepsis, it is not as commonly associated with IV line infections as the other pathogens listed.\n\nGiven these considerations, **Pseudomonas aeruginosa (A)** is a particularly virulent organism that is notorious for its ability to infect patients with compromised IV lines, especially in the setting of prolonged cannulation. Its association with hospital-acquired infections and its ability to form biofilms on catheters make it a likely cause of fever in this scenario.\n\n**Answer: A.**"}, {"branch": 8, "seed": 518018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 17.591102123260498, "model_output": "To approach this question, let's consider the key elements provided:\n\n1. **Patient Profile**: A 30-year-old female on prolonged IV cannulation.\n2. **Clinical Presentation**: A spike of fever.\n3. **Risk Factors**: Prolonged IV cannulation is a significant risk factor for catheter-related bloodstream infections (CRBSIs).\n\nGiven these points, let's evaluate the options:\n\nA. **Pseudomonas aeruginosa**: This is a gram-negative rod that is commonly associated with infections in immunocompromised patients, those with cystic fibrosis, or those who have been exposed to healthcare settings. It can cause infections in various sites, including the urinary tract, lungs, and bloodstream, especially in the context of indwelling catheters. Pseudomonas is known for its resistance to many antibiotics and is a common cause of CRBSIs, particularly in patients with prolonged IV access.\n\nB. **Coagulase-negative staphylococcus (CoNS)**: While CoNS, especially Staphylococcus epidermidis, is a common cause of CRBSIs, it is more often associated with the use of indwelling medical devices such as catheters. However, it is generally less virulent than Pseudomonas aeruginosa and more commonly associated with device-related infections rather than causing a \"spike\" of fever.\n\nC. **Streptococcus agalactiae (Group B Streptococcus)**: This bacterium is more commonly associated with infections in pregnant women, neonates, and the elderly, particularly those with underlying health conditions. It is less likely to be the cause of a CRBSI in a young, otherwise healthy female on IV antibiotics.\n\nD. **E. coli**: While E. coli can cause urinary tract infections and, in rare cases, bacteremia, it is not as commonly associated with CRBSIs in the context of prolonged IV cannulation as Pseudomonas aeruginosa.\n\nConsidering the clinical scenario of a young, otherwise healthy female with a spike of fever and prolonged IV cannulation, the most likely cause is an organism that is known for causing device-related infections and is particularly virulent in such contexts. Pseudomonas aeruginosa fits this profile best due to its association with healthcare-associated infections and its capacity to cause severe infections in individuals with prolonged exposure to invasive medical devices.\n\n**Answer: A.**"}, {"branch": 9, "seed": 519015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 16.878528833389282, "model_output": "To approach this question, let's consider the key points provided:\n\n1. **Patient's Condition**: The patient is a 30-year-old female on antibiotics with prolonged IV cannulation. Prolonged IV cannulation increases the risk of catheter-related bloodstream infections (CRBSIs), which are typically caused by organisms that are part of the skin flora or that can easily colonize the skin and subsequently the catheter.\n\n2. **Symptom of Spike in Fever**: Fever is a common symptom of infection. In the context of a patient with a medical device like an IV cannula, a sudden spike in fever often suggests a bacterial infection related to the device.\n\n3. **Common Causes of Catheter-Related Bloodstream Infections**:\n   - **Pseudomonas aeruginosa (A)**: Known for causing infections in patients with compromised immunity or those with medical devices. It's a common cause of CRBSIs, especially in patients with prolonged exposure to broad-spectrum antibiotics, which can disrupt normal flora and select for more resistant organisms like Pseudomonas.\n   - **Coagulase-negative staphylococcus (B)**: This group, particularly Staphylococcus epidermidis, is a common cause of CRBSIs. However, it's more often associated with biofilm formation on the catheter rather than a sudden spike in fever.\n   - **Streptococcus agalactiae (C)**: This is more commonly associated with infections in newborns and pregnant women, and while it can cause infections in adults, it's less commonly associated with CRBSIs compared to the other options.\n   - **E. coli (D)**: While E. coli can cause bloodstream infections, it is more commonly associated with urinary tract infections and less commonly with CRBSIs unless there is a urinary tract source.\n\nGiven the scenario of prolonged IV cannulation and a sudden spike in fever, the most likely cause would be an organism that is known for causing device-related infections, particularly in the setting of antibiotic use that could have disrupted normal flora. Pseudomonas aeruginosa is notorious for its association with such infections, especially in patients with risk factors like prolonged IV access and the use of broad-spectrum antibiotics, which can select for this pathogen.\n\nSo, the answer is A."}], "branch_preds": ["A", "A", "A", "A", "A", "A", "A", "A", "A", "A"], "metrics": {"leader": "A", "max_frac": 1.0, "variation_ratio": 0.0, "entropy_bits": 0.0, "valid_n": 10, "none_n": 0, "unanimous": true, "unanim_valid": true, "correct_fraction": 0.0, "leader_correct": false, "class": "unanimous", "wall_time_sec": 156.54513478279114, "mean_branch_time_sec": 15.652074909210205}}
{"index": 5, "picked_index": 6, "id": "defe1c85-63fe-4a16-ba10-b3749975818a", "question": "The cribriform plate connects:", "options": {"A": "Nasal cavity and anterior cranial fossa", "B": "Nasal cavity and orbit", "C": "Nasal cavity and oral cavity", "D": "Anterior cranial fossa and orbit"}, "gold": "A", "subject_name": "Anatomy", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:47:30.464719+00:00", "branches": [{"branch": 0, "seed": 610042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 15.430121898651123, "model_output": "To determine the correct answer, let's analyze the anatomy of the skull and the functions of the cribriform plate:\n\n1. **Location and Function**: The cribriform plate is a part of the ethmoid bone, which is a spongy bone located between the nasal cavity and the anterior cranial fossa. It forms part of the anterior cranial fossa's base. The ethmoid bone has a crucial role in separating the nasal cavity from the cranial cavity.\n\n2. **Anatomical Relationships**:\n   - **Nasal Cavity**: The cribriform plate forms the roof of the nasal cavity. It is perforated by numerous small foramina through which the olfactory nerves (cranial nerve I) pass, allowing for the transmission of olfactory information from the nasal mucosa to the brain.\n   - **Anterior Cranial Fossa**: The cribriform plate directly connects to the anterior cranial fossa, forming its base. The anterior cranial fossa is one of the three major divisions of the cranial fossae and contains the frontal lobe of the brain.\n\n3. **Eliminating Incorrect Options**:\n   - **B. Nasal cavity and orbit**: The cribriform plate does not connect to the orbit. The orbit is the bony cavity that contains the eyeball and associated structures, and it is separated from the nasal cavity by several bones, including the frontal, lacrimal, ethmoid, and sphenoid bones.\n   - **C. Nasal cavity and oral cavity**: The cribriform plate is part of the ethmoid bone that separates the nasal cavity from the cranial cavity, not the oral cavity. The oral cavity is a separate anatomical space that communicates with the nasal cavity through the nasopharynx.\n   - **D. Anterior cranial fossa and orbit**: This option is incorrect because, as explained, the cribriform plate does not connect to the orbit.\n\nGiven this analysis, the correct answer is the one that accurately describes the relationship between the cribriform plate and the two anatomical spaces it connects.\n\nAnswer: A."}, {"branch": 1, "seed": 611039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 14.6629798412323, "model_output": "To answer this question, let's analyze the anatomy of the skull and the specific functions and locations of the structures mentioned:\n\n1. **Understanding the Cribriform Plate**: The cribriform plate is a part of the ethmoid bone, which is a spongy bone located at the roof of the nasal cavity. The name \"cribriform\" means \"sieve-like,\" which gives a hint about its structure. It is characterized by many small foramina (openings) that allow the passage of the olfactory nerves (I cranial nerve) from the nasal cavity to the brain.\n\n2. **Analyzing the Options**:\n   - **A. Nasal cavity and anterior cranial fossa**: This option makes sense because the cribriform plate is situated at the roof of the nasal cavity and it connects this area with the anterior cranial fossa, where the olfactory bulbs are located. The olfactory nerves pass through the cribriform plate to reach the brain.\n   - **B. Nasal cavity and orbit**: The orbit is the bony cavity that houses the eye and its adnexa. While the ethmoid bone does have parts that form the medial wall of the orbit, the cribriform plate itself does not directly connect the nasal cavity to the orbit.\n   - **C. Nasal cavity and oral cavity**: The nasal cavity and oral cavity are two separate anatomical spaces, and the cribriform plate is specifically related to the nasal cavity, not the oral cavity.\n   - **D. Anterior cranial fossa and orbit**: This option is incorrect because, although the anterior cranial fossa is involved, the connection of the cribriform plate is specifically with the nasal cavity, not directly with the orbit.\n\n3. **Conclusion**: Based on the anatomical relationships and the specific role of the cribriform plate, it is clear that it connects the nasal cavity with the anterior cranial fossa, allowing for the passage of olfactory nerve fibers.\n\nThe correct answer is A."}, {"branch": 2, "seed": 612036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 11.983975648880005, "model_output": "To determine the correct connection of the cribriform plate, let's consider its anatomy and function. The cribriform plate is part of the ethmoid bone, which is a spongy bone located at the roof of the nasal cavity. The ethmoid bone serves as a bridge between the nasal cavity and the anterior cranial fossa. It has several important features, including the superior and middle nasal conchae, the lamina papyracea (which forms part of the medial wall of the orbit), and the cribriform plate.\n\nThe cribriform plate is named for its appearance, which is pierced by numerous small holes (foramina) through which the olfactory nerves (cranial nerve I) pass from the nasal mucosa to the olfactory bulbs in the anterior cranial fossa. This unique feature indicates its connection to the cranial cavity.\n\nGiven the options:\nA. Nasal cavity and anterior cranial fossa - This is the correct connection. The cribriform plate is located between these two structures, allowing for the passage of the olfactory nerves.\nB. Nasal cavity and orbit - While the ethmoid bone does have a part (the lamina papyracea) that is adjacent to the orbit, the cribriform plate itself does not connect the nasal cavity directly to the orbit.\nC. Nasal cavity and oral cavity - There is no direct connection between the cribriform plate and the oral cavity.\nD. Anterior cranial fossa and orbit - The cribriform plate connects the anterior cranial fossa to the nasal cavity, not directly to the orbit.\n\nTherefore, the correct answer is A."}, {"branch": 3, "seed": 613033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 12.666913986206055, "model_output": "To answer this question, let's consider the anatomy of the skull and the specific roles of the bones within it.\n\nThe cribriform plate is a part of the ethmoid bone, which is a spongy bone located at the roof of the nasal cavity. The ethmoid bone serves as a bridge between the nasal cavity and the cranial cavity, specifically the anterior cranial fossa. The cribriform plate is a thin, sieve-like part of the ethmoid bone that allows the passage of the olfactory nerves (cranial nerve I) from the nasal cavity to the brain. These nerves are responsible for the sense of smell.\n\n- Option A (Nasal cavity and anterior cranial fossa) is correct because the cribriform plate indeed connects the nasal cavity to the anterior cranial fossa, allowing the olfactory nerves to pass through.\n- Option B (Nasal cavity and orbit) is incorrect because the cribriform plate does not directly connect the nasal cavity to the orbit (the bony cavity that contains the eye). The ethmoid bone does have parts that form part of the medial wall of the orbit, but this is not the function of the cribriform plate.\n- Option C (Nasal cavity and oral cavity) is incorrect because the cribriform plate is not involved in connecting the nasal cavity to the oral cavity. The two cavities are separate and are connected by the nasopharynx.\n- Option D (Anterior cranial fossa and orbit) is incorrect because, while the ethmoid bone is involved in the anterior cranial fossa, the cribriform plate specifically connects the nasal cavity to the anterior cranial fossa, not directly to the orbit.\n\nSo, the correct answer is A."}, {"branch": 4, "seed": 614030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 18.95479106903076, "model_output": "To determine the correct answer, let's analyze the function and anatomical relationships of the cribriform plate:\n\n1. **Understanding the Cribriform Plate**: The cribriform plate is part of the ethmoid bone, which is located in the skull. It forms part of the anterior cranial fossa, the floor of the nasal cavity, and part of the lateral wall of the nasal cavity.\n\n2. **Anatomical Relationships**:\n   - The nasal cavity is the air-filled space within the nasal bones and the upper part of the nasal passages. It's where the air we breathe passes through before entering the pharynx.\n   - The anterior cranial fossa is the most forward part of the cranial cavity, housing the frontal lobe of the brain and the base of the frontal, ethmoid, and sphenoid bones.\n   - The orbit refers to the bony cavity that houses the eyeball and its associated muscles, nerves, and blood vessels.\n\n3. **Function of the Cribriform Plate**: The cribriform plate is particularly notable for containing numerous small foramina (openings) through which the olfactory nerves (I cranial nerve) pass from the nasal mucosa to the brain. This unique structure allows for the transmission of olfactory information from the nose to the brain.\n\n4. **Connecting Structures**: Given its location and function, the cribriform plate connects the nasal cavity (where olfactory receptors are located) with the anterior cranial fossa (where the olfactory bulbs are found), enabling the sense of smell.\n\n5. **Evaluating the Options**:\n   - A. Nasal cavity and anterior cranial fossa: This is consistent with the role of the cribriform plate in connecting the nasal cavity (where the olfactory receptors are) with the anterior cranial fossa (where the olfactory bulbs are located).\n   - B. Nasal cavity and orbit: The cribriform plate does not connect the nasal cavity with the orbit; the orbital floor is formed by a different part of the ethmoid bone and the maxilla.\n   - C. Nasal cavity and oral cavity: The cribriform plate is part of the nasal cavity's floor, not the oral cavity.\n   - D. Anterior cranial fossa and orbit: While both structures are in the vicinity, the cribriform plate specifically connects the nasal cavity to the anterior cranial fossa, not directly to the orbit.\n\nBased on the above analysis, the correct answer is the option that accurately describes the anatomical connection facilitated by the cribriform plate.\n\nAnswer: A."}, {"branch": 5, "seed": 615027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 15.707000732421875, "model_output": "To answer this question, let's consider the anatomy of the skull, particularly focusing on the structures that the cribriform plate is a part of.\n\n1. **Understanding the Cribriform Plate**: The cribriform plate is a part of the ethmoid bone. It is named for its sieve-like (cribriform) appearance due to numerous small foramina (openings) that allow for the passage of olfactory nerves from the nasal cavity to the brain.\n\n2. **Anatomical Location and Function**: The cribriform plate is located at the roof of the nasal cavity. Its primary role is to form part of the floor of the anterior cranial fossa and to provide a passage for the olfactory nerves (I cranial nerves) to reach the brain, where they synapse in the olfactory bulbs.\n\n3. **Options Analysis**:\n   - **A. Nasal cavity and anterior cranial fossa**: This option correctly identifies the cribriform plate's role in connecting the nasal cavity with the anterior cranial fossa, which houses the olfactory bulbs and the beginning of the brain's olfactory pathways.\n   - **B. Nasal cavity and orbit**: The cribriform plate does not directly connect the nasal cavity to the orbit. The orbit is the bony cavity that houses the eyeball and is located in the frontal bone and lesser wings of the sphenoid bone, not directly related to the cribriform plate.\n   - **C. Nasal cavity and oral cavity**: There is no direct connection between the cribriform plate and the oral cavity. The nasal cavity and oral cavity are two separate passages with different functions and anatomical connections.\n   - **D. Anterior cranial fossa and orbit**: While the cribriform plate does connect to the anterior cranial fossa, it does not connect it to the orbit. The anterior cranial fossa and the orbit are two distinct anatomical spaces.\n\n**Conclusion**: Based on the anatomical functions and locations, the correct answer is the one that accurately reflects the cribriform plate's role in connecting the nasal cavity with the anterior cranial fossa.\n\nAnswer: A."}, {"branch": 6, "seed": 616024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 16.159995317459106, "model_output": "To answer this question, let's analyze the anatomy of the skull, specifically focusing on the sphenoid bone and its components, as the cribriform plate is a part of this bone.\n\n1. **Location and Function**: The cribriform plate is a part of the ethmoid bone, which is located in the skull. The ethmoid bone is situated between the nasal cavity and the anterior cranial fossa. Its primary function is to provide a passage for the olfactory nerves (cranial nerve I) from the nasal cavity to the brain.\n\n2. **Anatomical Connections**: \n   - The **nasal cavity** is the space within the nose, where air enters and where the olfactory receptors are located.\n   - The **anterior cranial fossa** is the upper part of the cranial cavity that houses the frontal lobe of the brain. The cribriform plate forms part of the floor of this fossa.\n   - The **orbit** is the bony cavity that contains the eye and its associated structures.\n   - The **oral cavity** is the space within the mouth, which is not directly related to the cribriform plate's primary function or location.\n\n3. **Analyzing the Options**:\n   - **A. Nasal cavity and anterior cranial fossa**: This option aligns with the cribriform plate's role in providing a passage for the olfactory nerves from the nasal cavity to the anterior cranial fossa.\n   - **B. Nasal cavity and orbit**: This option is incorrect because the cribriform plate does not connect the nasal cavity to the orbit.\n   - **C. Nasal cavity and oral cavity**: This option is also incorrect as the cribriform plate is not involved in the connection between the nasal cavity and the oral cavity.\n   - **D. Anterior cranial fossa and orbit**: This option is incorrect because, while the cribriform plate does connect to the anterior cranial fossa, it does not connect it to the orbit.\n\nGiven this analysis, the correct answer is the one that correctly identifies the connection between the nasal cavity and the anterior cranial fossa through the cribriform plate.\n\nAnswer: A."}, {"branch": 7, "seed": 617021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 13.093904733657837, "model_output": "To determine the correct answer, let's analyze the anatomy of the cranial bones and their connections:\n\n1. **Understanding the cribriform plate**: The cribriform plate is part of the ethmoid bone. The ethmoid bone is a spongy bone that is located at the roof of the nasal cavity. The cribriform plate is a thin, sieve-like part of the ethmoid bone that forms the roof of the nasal cavity.\n\n2. **Anatomical Connections**:\n   - **A. Nasal cavity and anterior cranial fossa**: The cribriform plate indeed forms the roof of the nasal cavity and also serves as the floor of the anterior cranial fossa. This is a critical area because the olfactory nerves (cranial nerve I) pass through the cribriform plate to connect the nasal cavity with the brain.\n   - **B. Nasal cavity and orbit**: While the ethmoid bone does contribute to the orbital floor, the cribriform plate is not directly connected to the orbit; it's more related to the cranial cavity.\n   - **C. Nasal cavity and oral cavity**: The nasal cavity and oral cavity are separate structures, and the cribriform plate is specifically associated with the nasal cavity, not the oral cavity.\n   - **D. Anterior cranial fossa and orbit**: Although the cribriform plate is part of the anterior cranial fossa, it does not directly connect to the orbit. It connects the nasal cavity to the anterior cranial fossa.\n\nConsidering the above information, the cribriform plate's primary function and anatomical connections are with both the nasal cavity and the anterior cranial fossa, making it a critical structure for olfactory nerve passage and cranial cavity integrity.\n\nSo, the answer is A."}, {"branch": 8, "seed": 618018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 14.341655492782593, "model_output": "To determine the correct answer, let's analyze the function and location of the cribriform plate:\n\n1. **Location and Structure**: The cribriform plate is part of the ethmoid bone. It is situated at the roof of the nasal cavity. This bone is crucial because it forms part of the anterior cranial fossa, which is the uppermost part of the skull that contains the frontal lobe of the brain.\n\n2. **Function**: The name \"cribriform\" means \"sieve-like\" in Latin, which refers to the plate's unique structure. The cribriform plate contains numerous small holes (foramina) through which the olfactory nerves (I CN, cranial nerve I) pass. These nerves are responsible for transmitting sensory information related to smell from the olfactory receptors in the nasal cavity to the brain.\n\n3. **Anatomical Connections**: Given its role and location, the cribriform plate serves as a connection between the nasal cavity (where olfactory receptors are located) and the anterior cranial fossa (where the olfactory bulbs, which receive the olfactory nerve fibers, are housed).\n\nNow, let's evaluate the options:\n- A. Nasal cavity and anterior cranial fossa: This is consistent with the function and location of the cribriform plate.\n- B. Nasal cavity and orbit: The orbit (eye socket) is not directly connected by the cribriform plate; it is associated with different structures and bones.\n- C. Nasal cavity and oral cavity: The cribriform plate does not connect the nasal cavity to the oral cavity; these are two separate cavities with different functions and connections.\n- D. Anterior cranial fossa and orbit: This option is incorrect as the cribriform plate connects to the nasal cavity, not the orbit.\n\nTherefore, the correct answer is the one that accurately describes the connection between the nasal cavity and the anterior cranial fossa through the cribriform plate."}, {"branch": 9, "seed": 619015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "A", "is_correct": true, "inference_time_sec": 17.6659517288208, "model_output": "To determine the correct answer, let's analyze the anatomy of the skull, particularly focusing on the structures mentioned: the cribriform plate, nasal cavity, anterior cranial fossa, orbit, and their connections.\n\n1. **Nasal Cavity**: This is the air-filled space within the nasal bones and the nasal passages. It is divided into two nostrils and the nasal septum.\n\n2. **Anterior Cranial Fossa**: This is the upper part of the cranial cavity that accommodates the frontal lobe of the brain. It is one of the four cranial fossae and is located at the front of the skull.\n\n3. **Orbit**: The orbit, or eye socket, is the bony cavity that contains and protects the eyeball and its associated muscles, nerves, and blood vessels.\n\n4. **Cribriform Plate**: The cribriform plate is a part of the ethmoid bone. It is a thin, perforated plate that forms part of the anterior cranial fossa. The cribriform plate is significant because it contains olfactory nerves (cranial nerve I) that pass through it, connecting the nasal cavity to the brain.\n\n- **Option A (Nasal cavity and anterior cranial fossa)**: The cribriform plate specifically connects the nasal cavity (through the olfactory nerves) to the anterior cranial fossa, which houses the frontal lobe of the brain and contains the olfactory bulb where the olfactory nerves terminate.\n\n- **Option B (Nasal cavity and orbit)**: There is no direct connection between the cribriform plate and the orbit in terms of the cribriform plate's function or structure.\n\n- **Option C (Nasal cavity and oral cavity)**: The cribriform plate is part of the nasal cavity, not the oral cavity. The oral cavity is connected to the nasal cavity through different structures, such as the choanae at the back of the nasal cavity, but not through the cribriform plate.\n\n- **Option D (Anterior cranial fossa and orbit)**: While the anterior cranial fossa and the orbit are both located in the skull, the cribriform plate specifically connects the nasal cavity to the anterior cranial fossa, not directly to the orbit.\n\nBased on the anatomical connections, the correct answer is the one that accurately describes the relationship between the cribriform plate and the structures it connects.\n\nAnswer: A."}], "branch_preds": ["A", "A", "A", "A", "A", "A", "A", "A", "A", "A"], "metrics": {"leader": "A", "max_frac": 1.0, "variation_ratio": 0.0, "entropy_bits": 0.0, "valid_n": 10, "none_n": 0, "unanimous": true, "unanim_valid": true, "correct_fraction": 1.0, "leader_correct": true, "class": "unanimous", "wall_time_sec": 150.69053769111633, "mean_branch_time_sec": 15.066729044914245}}
{"index": 6, "picked_index": 7, "id": "4e9a8341-05b8-4b00-859b-7a13d13b81a0", "question": "Which of the following headgear is preferred while treating a class II div. 1 malocclusion with a horizontal growth trend?", "options": {"A": "High pull head gear", "B": "Medium pull head gear", "C": "Cervical head gear", "D": "Reverse pull head gear"}, "gold": "C", "subject_name": "Dental", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:50:09.906595+00:00", "branches": [{"branch": 0, "seed": 710042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "C", "is_correct": true, "inference_time_sec": 14.559028148651123, "model_output": "When treating a Class II division 1 malocclusion with a horizontal growth pattern, the goal of orthodontic treatment is to correct the excessive mandibular growth or to encourage more forward growth of the maxilla. Here's a brief overview of the headgear options provided:\n\nA. **High pull headgear**: This type of headgear applies a force to the upper teeth or molars, pulling them backward. It's typically used in cases where there's a need to retract the maxilla or to correct an open bite, which might not be the primary concern in a Class II division 1 case with a horizontal growth pattern.\n\nB. **Medium pull headgear**: This is not a standard classification in orthodontic headgear. The typical classifications include high pull, low pull, and cervical pull, among others.\n\nC. **Cervical headgear**: This type of headgear is applied to the cervical region of the head, behind the ears, and pulls the upper teeth or molars backward. It's often used in growing patients to correct a Class II malocclusion by countering the horizontal growth pattern, thus it is effective in a Class II division 1 case with a horizontal growth trend. It can also help in reducing the overjet and proclination of the upper incisors.\n\nD. **Reverse pull headgear**: This is not a standard term used in orthodontic treatment. It's possible there might be confusion with the \"reverse headgear\" which is not a standard classification, or it might be a misunderstanding of the direction of force application in other types of headgear.\n\nConsidering the goal of treatment for a Class II division 1 malocclusion with a horizontal growth trend is to address the forward growth of the mandible or to correct the overjet, cervical headgear is often the preferred choice as it can effectively counteract the horizontal growth pattern without the need for intrusive forces on the upper teeth, which could be detrimental in cases with significant vertical discrepancies.\n\nSo, the answer is C."}, {"branch": 1, "seed": 711039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "C", "is_correct": true, "inference_time_sec": 17.487661600112915, "model_output": "To address a Class II division 1 malocclusion with a horizontal growth trend, we need to consider the type of headgear that would effectively counteract the excessive vertical or horizontal growth pattern, or both, to correct the overjet and/or molar relationship issues.\n\n- **Class II division 1** malocclusion is characterized by a protrusive upper central incisors, a retroclined upper central incisors, and a Class II molar relationship, with the lower molars distal to the upper molars. The \"1\" in Class II division 1 refers to the presence of a protrusive upper central incisor and retroclined upper lateral incisors.\n\n- **Horizontal growth trend** indicates that the maxilla (upper jaw) is growing more horizontally than the mandible (lower jaw), contributing to the Class II malocclusion.\n\n- **Headgear** is an orthodontic appliance used to modify the growth of the jaws and teeth, and it can be categorized based on its point of attachment and direction of force application.\n\n- **High pull headgear** (A) is attached above the head and pulls the head back, which is more effective for vertical control and can be used in cases with a vertical growth pattern or when there is a need to intrude the maxilla. It's not the most effective choice for a horizontal growth pattern.\n\n- **Medium pull headgear** (B) is not a commonly used classification in the same way as high pull or cervical headgear. The terms often refer to the specific design and application of force, rather than a distinct category of headgear for specific growth patterns.\n\n- **Cervical headgear** (C) is attached to the cervical area of the maxillary teeth and pulls the maxilla backward, which is effective for horizontal growth patterns. It's specifically designed to influence the maxillary growth by pulling it backward, countering the horizontal growth trend seen in Class II division 1 malocclusions.\n\n- **Reverse pull headgear** (D) is not a standard term used in orthodontics for the common classifications of headgear used in the treatment of Class II malocclusions.\n\nGiven the need to counteract a horizontal growth trend in a Class II division 1 malocclusion, cervical headgear (C) is the most appropriate choice because it directly addresses the horizontal growth pattern by pulling the maxilla backward.\n\nSo, the answer is C."}, {"branch": 2, "seed": 712036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "C", "is_correct": true, "inference_time_sec": 13.371645450592041, "model_output": "To address a Class II division 1 malocclusion with a horizontal growth pattern, the primary goal of orthodontic treatment is to counteract the excessive mandibular growth or to promote forward growth of the upper jaw to improve the alignment of the teeth and the occlusion. Here's a brief overview of the options provided:\n\nA. High pull headgear: This type of headgear applies force upward and backward, which is more effective in treating vertical discrepancies rather than horizontal growth patterns. It's not the first choice for a Class II division 1 with a horizontal growth trend.\n\nB. Medium pull headgear: Medium pull headgear is designed to apply a force that is more forward and upward, but it's not as commonly used or as specifically tailored for horizontal growth patterns as other options.\n\nC. Cervical headgear: This type of headgear is positioned at the neck and applies force to the upper teeth and jaw. It can influence the forward growth of the upper jaw (maxilla) or restrain the backward growth of the lower jaw (mandible), making it a suitable option for addressing a Class II division 1 malocclusion with a horizontal growth pattern.\n\nD. Reverse pull headgear: Reverse pull headgear applies force in the opposite direction of the typical headgear, which means it pulls the upper jaw backward and downward. This is not suitable for a Class II division 1 with a horizontal growth trend, as it would exacerbate the condition by reducing the forward position of the upper jaw relative to the lower jaw.\n\nConsidering the need to influence the horizontal growth pattern in a Class II division 1 malocclusion, cervical headgear (Option C) is often preferred because it can effectively promote forward growth of the maxilla or restrain the backward growth of the mandible, thereby correcting the malocclusion.\n\nSo, the answer is C."}, {"branch": 3, "seed": 713033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "C", "is_correct": true, "inference_time_sec": 13.348142385482788, "model_output": "To address a Class II Division 1 malocclusion with a horizontal growth trend, it's essential to understand the characteristics of the condition and the effects of different types of headgear.\n\nA Class II Division 1 malocclusion is characterized by a retrognathic (underdeveloped) lower jaw relative to the upper jaw, often with a protrusive upper central incisors. The horizontal growth pattern indicates that the growth of the mandible (lower jaw) is more horizontal than vertical.\n\nLet's evaluate the options:\n\nA. High Pull Headgear (HPHG): This type of headgear is used to correct Class II malocclusions but primarily by countering the vertical growth of the upper jaw. It's not ideal for a horizontal growth pattern, as it doesn't directly address the horizontal deficiency of the lower jaw.\n\nB. Medium Pull Headgear: This is less commonly discussed and not as standard as other types of headgear for specific growth pattern correction. It might not be the first choice for a horizontal growth trend.\n\nC. Cervical Headgear (CHG): Cervical headgear is specifically designed to influence the mandible's growth by pulling the chin forward. It is particularly useful in cases where there is a horizontal growth pattern, as it encourages the mandible to grow forward and downward, countering the Class II Division 1 malocclusion.\n\nD. Reverse Pull Headgear: This type of headgear is not commonly used for Class II correction and would not be the preferred choice for a horizontal growth trend. It would not effectively address the horizontal deficiency of the mandible.\n\nGiven the horizontal growth trend in a Class II Division 1 malocclusion, the most appropriate headgear would be the one that directly encourages forward and downward growth of the lower jaw, which is the Cervical Headgear.\n\nSo, the answer is C."}, {"branch": 4, "seed": 714030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "C", "is_correct": false, "inference_time_sec": 17.235459804534912, "model_output": "To address a Class II division 1 malocclusion with a horizontal growth trend, it's essential to understand the nature of the malocclusion and the growth pattern of the patient. A Class II division 1 malocclusion is characterized by a protrusive upper central incisors and a retroclined lower incisors, often associated with a retrognathic (underdeveloped) lower jaw relative to the upper jaw. The horizontal growth trend indicates that the growth of the upper jaw is more forward (horizontal) compared to the lower jaw, which is crucial for treatment planning.\n\n- **High Pull Headgear (Option A)**: This type of headgear is used to restrain the forward growth of the upper jaw. It is more effective in vertical growth patterns where the upper jaw is growing downward, not ideal for a horizontal growth trend.\n\n- **Medium Pull Headgear (Option B)**: Similar to high pull headgear, medium pull headgear also has a forward vector that could potentially exacerbate a horizontal growth pattern, as it may not adequately address the horizontal aspect of the growth trend.\n\n- **Cervical Headgear (Option C)**: Cervical headgear applies a force to the cervical region of the upper teeth and is designed to influence the forward growth of the upper jaw. However, its effectiveness in altering the horizontal growth pattern of the maxilla is limited, and it might not be the best choice for a horizontal growth trend where the need is to influence the vertical or sagittal (side to side) growth more significantly.\n\n- **Reverse Pull Headgear (Option D)**: Reverse pull headgear, also known as Class II elastics, works by pulling the upper molars backward. This action can help to correct a Class II malocclusion by countering the horizontal growth trend of the upper jaw. It encourages the upper jaw to grow less forward or even backward relative to the lower jaw, which is beneficial in cases with a horizontal growth trend.\n\nConsidering the need to address a Class II division 1 malocclusion with a horizontal growth trend, the most appropriate headgear would be the one that counters this horizontal growth pattern. Therefore, the best option is the reverse pull headgear, as it directly influences the sagittal relationship by pulling the upper molars backward, which can help to correct the horizontal growth trend and the Class II malocclusion.\n\nSo, the answer is D."}, {"branch": 5, "seed": 715027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "C", "is_correct": true, "inference_time_sec": 15.493788242340088, "model_output": "To address a Class II Division 1 malocclusion with a horizontal growth trend, it's essential to understand the goals of treatment and the mechanisms of action of the different types of headgear.\n\nA Class II Division 1 malocclusion is characterized by a retroclined upper central incisors and a Class II molar relationship, often with a convex facial profile. In a patient with a horizontal growth trend, the growth pattern favors a forward growth of the maxilla and/or a backward growth of the mandible. The goal of treatment is to correct the molar relationship, improve the alignment of the teeth, and address the facial profile.\n\nLet's consider the options:\n\nA. High pull headgear: This type of headgear pulls the maxilla backward, which is generally not ideal for a Class II Division 1 malocclusion with a horizontal growth pattern, as it could potentially exacerbate the underbite.\n\nB. Medium pull headgear: Similar to high pull headgear, medium pull headgear can also pull the maxilla backward, which is not the most effective approach for a Class II Division 1 malocclusion with a horizontal growth pattern.\n\nC. Cervical headgear: This type of headgear is designed to pull the mandible backward and the maxilla forward, which is beneficial for a Class II Division 1 malocclusion with a horizontal growth trend. It helps to correct the molar relationship, improve the overjet, and can also influence the facial profile by encouraging a more forward growth of the maxilla.\n\nD. Reverse pull headgear: Reverse pull headgear pulls the maxilla forward, which is not typically used for a Class II Division 1 malocclusion, especially with a horizontal growth trend, as it might not address the primary issues of overjet and molar relationship.\n\nConsidering the growth pattern and the need to correct a Class II Division 1 malocclusion, cervical headgear (C) is the most appropriate choice because it addresses the need to pull the mandible backward and the maxilla forward, thus correcting the molar relationship and the facial profile.\n\nSo, the answer is C."}, {"branch": 6, "seed": 716024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "C", "is_correct": true, "inference_time_sec": 15.874776363372803, "model_output": "To address a Class II division 1 malocclusion with a horizontal growth trend, we need to consider the type of headgear that will effectively counteract the excessive mandibular growth or insufficient maxillary growth, or both, while also taking into account the direction of the growth pattern.\n\n- **Class II division 1 malocclusion** typically presents with a protrusive upper central incisors and a retrognathic (set back) mandible, often with a horizontal growth pattern, which means the lower jaw is growing forward more than the upper jaw.\n\n- **A. High pull headgear** applies a force upward and backward on the maxilla. It's more commonly used in cases where there's a significant overbite or a severe Class II skeletal pattern. It may not be the best choice for a horizontal growth pattern.\n\n- **B. Medium pull headgear** also applies a force to the maxilla, but it's less intense than high pull headgear. It can be used in various types of malocclusions, but it's not specifically tailored to counteract a horizontal growth pattern.\n\n- **C. Cervical headgear** applies a force to the cervical region of the maxilla, pulling it backward and downward. This type of headgear is particularly useful for countering the effects of a horizontal growth pattern in Class II division 1 malocclusions. It helps to correct the retrognathic mandible by pulling the maxilla back and downward, which can help to reduce the Class II relationship and improve the anteroposterior (forward and backward) relationship of the jaws.\n\n- **D. Reverse pull headgear** applies a force to the maxilla to pull it forward. This would be counterproductive in treating a Class II division 1 malocclusion with a horizontal growth trend, as it would exacerbate the existing skeletal discrepancy.\n\nGiven the need to correct a Class II division 1 malocclusion with a horizontal growth trend, the most appropriate type of headgear would be one that can effectively counteract the excessive forward growth of the mandible and the insufficient forward growth of the maxilla, which is the cervical headgear.\n\nSo, the answer is C."}, {"branch": 7, "seed": 717021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "C", "is_correct": false, "inference_time_sec": 19.221269845962524, "model_output": "To approach this question, let's break down the key components and understand the treatment goals and mechanics for a Class II division 1 malocclusion with a horizontal growth trend, as well as the mechanics of the headgear options provided.\n\n1. **Understanding Class II Division 1 Malocclusion**: This type of malocclusion is characterized by a retrognathic (underdeveloped) lower jaw relative to the upper jaw, with the upper central incisors significantly protruding forward. The horizontal growth trend indicates that the patient's facial growth pattern is more aligned with a forward and downward growth of the maxilla (upper jaw) compared to the mandible (lower jaw).\n\n2. **Treatment Goals**: The primary goal in treating a Class II division 1 malocclusion with a horizontal growth pattern is to correct the Class II relationship by either advancing the mandible or restraining the maxilla's growth to bring it more into alignment with the mandible. Additionally, addressing the protrusion of the upper central incisors is a key aspect of the treatment.\n\n3. **Headgear Options**:\n   - **A. High Pull Headgear**: This type of headgear pulls the upper teeth backward and the maxilla upward. It is often used to correct a Class II malocclusion by countering the forward growth of the maxilla and advancing the mandible.\n   - **B. Medium Pull Headgear**: This is not as commonly referenced in standard orthodontic practice as the other options and does not specifically target the growth patterns described for Class II division 1 malocclusions with a horizontal growth trend.\n   - **C. Cervical Headgear**: This type of headgear is designed to exert a force to the upper teeth and the upper jaw, primarily used for Class II corrections. However, it tends to pull the maxilla back but does not specifically address the forward and downward growth pattern.\n   - **D. Reverse Pull Headgear**: This type of headgear is not standard in orthodontic practice and does not align with the treatment goals for a Class II division 1 malocclusion with a horizontal growth trend.\n\nConsidering the specific needs of a Class II division 1 malocclusion with a horizontal growth trend, where the maxilla is growing forward and downward relative to the mandible, the most effective type of headgear would be one that can counteract this forward and upward growth of the maxilla while also addressing the protrusion of the upper central incisors. High pull headgear is specifically designed to achieve this by pulling the upper teeth back and the maxilla upward, making it the preferred choice for this scenario.\n\nSo, the answer is A."}, {"branch": 8, "seed": 718018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "C", "is_correct": false, "inference_time_sec": 12.46059250831604, "model_output": "To address a Class II Division 1 malocclusion with a horizontal growth pattern, we need to consider the direction of force and the growth pattern of the patient. Here's a breakdown of the options provided:\n\nA. High pull headgear: This type of headgear applies force to the back of the head, pulling the mandible (lower jaw) backward. It's typically used for patients with a vertical growth pattern, not horizontal.\n\nB. Medium pull headgear: This type of headgear also pulls the mandible backward but with a less intense force compared to high pull headgear. It's not specifically indicated for a horizontal growth pattern.\n\nC. Cervical headgear: Cervical headgear is designed to pull the mandible forward, which is counterproductive for a Class II Division 1 malocclusion, where the upper jaw (maxilla) is ahead of the lower jaw (mandible). It's more commonly used in Class III cases or for vertical growth control.\n\nD. Reverse pull headgear (also known as facemask therapy for some, though the term \"reverse pull\" is more commonly used for headgear in the context of Class II corrections): This type of headgear pulls the maxilla forward, which is the desired effect for treating a Class II Division 1 malocclusion with a horizontal growth pattern. It counteracts the forward growth of the maxilla and encourages the mandible to grow forward, thereby correcting the Class II relationship.\n\nGiven the need to correct a Class II Division 1 malocclusion with a horizontal growth pattern, the most appropriate choice would be to apply force to move the maxilla forward, which is achieved with reverse pull headgear.\n\nSo, the answer is D."}, {"branch": 9, "seed": 719015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "C", "is_correct": true, "inference_time_sec": 20.34862494468689, "model_output": "To approach this question, let's break down the key components and the treatment options for a Class II Division 1 malocclusion with a horizontal growth trend.\n\n1. **Class II Division 1 Malocclusion**: This is characterized by a distal relationship between the maxillary and mandibular dental arches (overjet) and a protrusive upper central incisors relative to the lower central incisors. It's often associated with a retrognathic (underdeveloped) lower jaw and a prognathic (overdeveloped) upper jaw.\n\n2. **Horizontal Growth Trend**: This refers to a pattern of facial growth where the width of the maxillary and mandibular dental arches increases more than the vertical growth, leading to a broad, flat facial profile. It is less conducive to vertical control of the mandible, which is often needed in Class II corrections to counteract the retrognathic growth pattern.\n\n3. **Treatment Options**:\n   - **A. High Pull Headgear**: This type of headgear applies a force upward and backward on the maxilla. It is typically used to correct Class II malocclusions by countering the forward position of the upper teeth and promoting a more posterior position. However, it does not directly address the horizontal growth pattern and can sometimes exacerbate it by pulling the maxilla back without effectively guiding vertical growth.\n   - **B. Medium Pull Headgear**: Similar to high pull headgear, medium pull also applies a backward force but is generally not as strong as high pull. It might not be as effective in significant Class II corrections, especially in cases with a horizontal growth pattern.\n   - **C. Cervical Headgear**: This type of headgear applies force through the cervical region of the upper teeth. It is more effective for vertical control, as it can help to restrict or redirect the growth of the maxilla and mandible in a more vertical direction, which is beneficial for patients with a horizontal growth pattern. It's particularly useful for Class II patients where a vertical component of the correction is needed to address the retrognathic lower jaw.\n   - **D. Reverse Pull Headgear**: This type of headgear pulls the mandible forward, which is more typically used in Class III malocclusions where the lower jaw is prognathic (overdeveloped).\n\nConsidering the need for vertical control in a patient with a Class II Division 1 malocclusion and a horizontal growth trend, the most appropriate headgear would be one that can effectively counteract the horizontal growth pattern and encourage a more vertical development of the jaws. Cervical headgear is the best choice because it provides the necessary vertical control and can help to correct the Class II malocclusion by influencing the growth of the jaws in a more favorable direction.\n\nSo, the answer is C."}], "branch_preds": ["C", "C", "C", "C", "D", "C", "C", "A", "D", "C"], "metrics": {"leader": "C", "max_frac": 0.7, "variation_ratio": 0.30000000000000004, "entropy_bits": 1.1567796494470395, "valid_n": 10, "none_n": 0, "unanimous": false, "unanim_valid": false, "correct_fraction": 0.7, "leader_correct": true, "class": "lead50", "wall_time_sec": 159.42552828788757, "mean_branch_time_sec": 15.940098929405213}}
{"index": 7, "picked_index": 8, "id": "e2dd93d8-8047-4e9a-9389-e2b1781f8a35", "question": "Which is the most conspicuous sign in breast cancer?", "options": {"A": "Nipple retraction", "B": "Peau d'orange", "C": "Puckering", "D": "Cancer en-cuirasse"}, "gold": "B", "subject_name": "Surgery", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:52:21.098601+00:00", "branches": [{"branch": 0, "seed": 810042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 12.920810222625732, "model_output": "To determine the most conspicuous sign in breast cancer, let's evaluate each option:\n\nA. Nipple retraction: This is often considered one of the earliest and most common signs of breast cancer. It can occur due to a tumor pulling the nipple inward. It's frequently associated with an underlying breast cancer, especially in the ductal type.\n\nB. Peau d'orange (Skin of the orange): This is a condition where the skin of the breast looks like the peel of an orange due to lymphedema (swelling caused by a blockage in the lymphatic system). It's a sign of more advanced breast cancer, often associated with inflammatory breast cancer, which is a rare but aggressive form of the disease.\n\nC. Puckering: Puckering or dimpling of the skin can be a sign of breast cancer, particularly if it's associated with a palpable mass or a change in the skin's texture. However, it is less specific than nipple retraction and can be seen in other benign conditions as well.\n\nD. Cancer en-cuirasse (Cancer en-cuirasse or \"armor plating\"): This is a very rare condition where the breast becomes hard and immobile, resembling armor plating, due to extensive skin and subcutaneous tissue involvement by cancer. It's indicative of an advanced stage of the disease.\n\nConsidering the options, nipple retraction (A) is generally the most common and earliest noticeable sign of breast cancer, making it a significant indicator that warrants further investigation. While peau d'orange, puckering, and cancer en-cuirasse are also associated with breast cancer, they are typically seen in more advanced stages or in specific types of breast cancer, making nipple retraction the most conspicuous sign in the context of early detection.\n\nAnswer: A."}, {"branch": 1, "seed": 811039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 11.159731388092041, "model_output": "To determine the most conspicuous sign in breast cancer, let's analyze each option:\n\nA. Nipple retraction: This refers to the inward movement of the nipple, which can be caused by a tumor pulling on the ducts of the breast. It is a common symptom associated with breast cancer, particularly ductal carcinoma. Nipple retraction is often one of the first signs that prompt a woman to seek medical attention for breast changes.\n\nB. Peau d'orange: Also known as \"orange peel skin,\" this is a texture change in the skin of the breast, resembling the skin of an orange. It's caused by lymphedema (swelling due to blockage of lymphatic vessels) and is a sign of advanced breast cancer. While it's significant, it usually occurs in later stages.\n\nC. Puckering: Puckering or dimpling of the skin can be a sign of an underlying tumor, particularly in cases of inflammatory breast cancer. However, it's less commonly the first or most noticeable sign compared to nipple retraction.\n\nD. Cancer en-cuirasse: This term refers to a condition where the skin of the breast becomes hard and thick, often associated with inflammatory breast cancer. Like peau d'orange, it is a sign of advanced disease and is less likely to be the first sign noticed.\n\nConsidering the options, nipple retraction (A) is often the most noticeable and earliest sign of breast cancer, as it can be easily observed by the patient and prompts an immediate evaluation.\n\nSo, the answer is A."}, {"branch": 2, "seed": 812036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 13.924561500549316, "model_output": "To determine the most conspicuous sign in breast cancer, let's evaluate each option:\n\nA. Nipple retraction: Nipple retraction is indeed a common symptom of breast cancer. It occurs when a tumor in the breast pulls the nipple inward. This sign is often associated with more advanced breast cancers, particularly those that involve the ducts beneath the nipple, such as ductal carcinoma in situ (DCIS) or invasive ductal carcinoma. Nipple retraction can be a very noticeable and concerning symptom for patients and is often highlighted as a red flag in breast cancer screening.\n\nB. Peau d'orange (Skin of the orange): This term describes a condition where the skin of the breast looks like the skin of an orange due to lymphedema. It's a sign of inflammatory breast cancer, which is a rare and aggressive form of breast cancer. While alarming, it is less common than other types of breast cancer.\n\nC. Puckering: Puckering refers to a dimpling or wrinkling of the skin of the breast. This can be a sign of breast cancer, particularly if the puckering is due to a tumor pulling on the skin. However, it is not as universally recognized or as specific to breast cancer as nipple retraction.\n\nD. Cancer en-cuirasse (Cancer en-cuirasse or \"in armor\"): This term describes a thickened, hard, and often irregularly shaped breast that resembles armor. It is indicative of a large, advanced breast cancer that has infiltrated the skin and caused significant fibrosis. While it is a serious sign, it is not as commonly seen or as immediately noticeable as nipple retraction in the early stages of breast cancer.\n\nConsidering the frequency and universality of recognition, nipple retraction is generally considered the most conspicuous sign of breast cancer, as it is a symptom that can be easily observed by both patients and healthcare providers during a clinical examination.\n\nAnswer: A."}, {"branch": 3, "seed": 813033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 15.773060321807861, "model_output": "To approach this question, let's consider the characteristics and clinical manifestations of each option in the context of breast cancer:\n\nA. Nipple retraction: This refers to the inward pulling or drawing of the nipple into the breast. It can be a sign of breast cancer, particularly if associated with other symptoms like a mass or discharge. Nipple retraction can occur due to an underlying tumor pulling on the ducts or surrounding tissue, leading to the nipple's inward movement.\n\nB. Peau d'orange (French for \"skin of the orange\"): This term describes a condition where the skin of the breast resembles the texture of an orange peel, which is due to lymphedema (swelling caused by a blockage in the lymphatic system). While it can be associated with breast cancer, especially in advanced stages where the lymph nodes are involved, it is not as specific or early a sign as some other symptoms.\n\nC. Puckering: This refers to the appearance of the skin of the breast, which may look wrinkled or puckered due to the contraction of the skin from a tumor or scarring. While puckering can be a sign of breast cancer, it is often less specific than other symptoms, as it can also result from other conditions, such as a benign process or prior surgery.\n\nD. Cancer en-cuirasse (also known as \"cancer en-cuirasse\" or \"en-cuirass\" which means \"in armor\" in French): This term describes a type of breast cancer where the skin of the breast becomes hard, thickened, and often turns a bluish-red color, giving it a \"leather-like\" appearance. This condition is associated with inflammatory breast cancer, a rare and aggressive form of breast cancer. However, it is less common than other types of breast cancer and typically presents with other symptoms such as rapid onset of swelling, redness, and warmth of the breast.\n\nConsidering the specificity and the frequency of occurrence as a presenting sign, nipple retraction is often highlighted as one of the most common and conspicuous early signs of breast cancer, especially when it is associated with other risk factors or symptoms.\n\nSo, the answer is A."}, {"branch": 4, "seed": 814030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 13.922377586364746, "model_output": "To determine the most conspicuous sign in breast cancer, let's analyze each option:\n\nA. Nipple retraction: Nipple retraction is a significant symptom that often indicates an underlying breast cancer. The retraction can occur due to the pull of a tumor on the nipple-areolar complex or due to inflammatory changes in the breast tissue. It's a noticeable change that patients often report and is commonly associated with breast cancer.\n\nB. Peau d'orange: This term, French for \"skin of the orange,\" describes a condition where the skin of the breast looks like the peel of an orange. It's caused by lymphedema (swelling) and thickening of the skin due to a tumor blocking the lymphatic vessels. While it is a sign of breast cancer, it's more of a skin change rather than a direct sign of the cancer itself.\n\nC. Puckering: Puckering or dimpling of the skin can be a sign of breast cancer, but it's less specific and can also be caused by other benign conditions such as fibroadenomas or even skin infections. It's a change that can be noticed but might not be as directly indicative of cancer as some other signs.\n\nD. Cancer en-cuirasse: This term is less commonly used and refers to a situation where the skin of the breast becomes fixed to underlying structures, such as the pectoralis muscle or the chest wall, due to direct invasion by the tumor. While it is a sign of advanced breast cancer, it is less commonly observed in the early stages of the disease and might not be as noticeable or the first sign of cancer.\n\nConsidering the options, nipple retraction is often cited as one of the most alarming and specific signs of breast cancer, especially when associated with other symptoms or risk factors. It is a symptom that warrants immediate medical attention and is frequently highlighted in clinical guidelines and public health campaigns for breast cancer awareness.\n\nAnswer: A."}, {"branch": 5, "seed": 815027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 12.473585844039917, "model_output": "To determine the most conspicuous sign in breast cancer, let's analyze each option:\n\nA. Nipple retraction: This is a common symptom associated with breast cancer, particularly when it involves the skin of the breast or when a tumor is located in the upper part of the breast. Nipple retraction can be a significant sign, especially if it's unilateral and associated with other symptoms like nipple discharge or skin changes.\n\nB. Peau d'orange (Skin of the orange): This condition, also known as \"orange peel skin,\" is a result of lymphedema leading to skin thickening and a texture resembling the skin of an orange. It's a concerning sign, often associated with more advanced breast cancer, particularly inflammatory breast cancer, but it's not as specific or early a sign as some other symptoms.\n\nC. Puckering: Puckering of the skin is another sign that can be associated with breast cancer, especially when a tumor is causing the skin to pucker inward. However, it's less commonly the first or most noticeable sign compared to nipple retraction.\n\nD. Cancer en-cuirasse (Cancer en-cuirasse, also known as \"inflammatory breast cancer\" when referring to a specific aggressive form): This is a rare and aggressive form of breast cancer characterized by the cancer cells blocking lymphatic vessels, leading to rapid onset of symptoms like swelling, redness, and sometimes warmth of the breast. While alarming, it's not the most common or early sign of breast cancer.\n\nConsidering the above explanations, the most conspicuous and often one of the earliest signs of breast cancer, especially in its early stages, is nipple retraction. It's a symptom that warrants immediate medical attention and evaluation.\n\nAnswer: A."}, {"branch": 6, "seed": 816024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 12.413739919662476, "model_output": "To determine the most conspicuous sign in breast cancer, let's examine each option:\n\nA. Nipple retraction: This is often considered a classic and early sign of breast cancer, particularly in cases where the cancer is located in the upper, outer quadrant of the breast. The retraction is due to the pulling of the nipple-areola complex by the tumor, which can be caused by direct invasion of the cancer cells into the ducts of the breast or by the formation of a tumor beneath the nipple.\n\nB. Peau d'orange: This French term translates to \"orange peel skin\" and is a sign of inflammatory breast cancer. It's caused by the blockage of lymphatic vessels by cancer cells, leading to edema and the appearance of the skin resembling the peel of an orange. While it is a significant sign, it is less common and usually associated with a more aggressive and advanced form of breast cancer.\n\nC. Puckering: Puckering or dimpling of the skin can be a sign of breast cancer, but it is not as specific or as common as nipple retraction. It is often due to the inward retraction of the skin by a tumor beneath it.\n\nD. Cancer en-cuirasse: This is a rare form of breast cancer that presents as a hard, thick, leathery, and often painless mass. It is usually seen in older women and is not the most common or conspicuous sign of breast cancer.\n\nConsidering the options, nipple retraction (A) is the most frequently encountered and significant early sign of breast cancer, especially in women who do not have a family history or genetic predisposition, and it often prompts medical evaluation and diagnosis.\n\nSo, the answer is A."}, {"branch": 7, "seed": 817021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 12.25178861618042, "model_output": "To approach this question, let's analyze each option in the context of breast cancer signs:\n\nA. Nipple retraction: This is often considered one of the earliest and most specific signs of breast cancer, particularly in the context of breast cancer that has invaded the ducts. It's a noticeable change where the nipple is pulled inward, which can be caused by a tumor pulling on the ducts that lead to the nipple.\n\nB. Peau d'orange (also known as \"orange peel skin\"): This is a skin condition associated with breast cancer where the skin of the breast takes on a texture similar to an orange peel, due to lymphedema (swelling) caused by the blockage of lymphatic vessels by cancer cells. While it's a significant sign, it's not as directly indicative of cancer as nipple retraction.\n\nC. Puckering: This can be a sign of breast cancer, particularly if it's associated with a palpable mass or skin changes. However, it's not as specific as nipple retraction, as puckering can also be seen in benign conditions like fibroadenomas or even normal anatomical variations.\n\nD. Cancer en-cuirasse: This term refers to a rare and advanced form of breast cancer where the skin of the breast becomes hard and leathery, often associated with an underlying tumor that has grown into the skin. While it's a concerning sign, it's less common and typically seen in more advanced stages of the disease.\n\nConsidering the options, nipple retraction is often cited as one of the earliest and most specific signs of breast cancer, making it the most conspicuous and indicative of a potential malignancy among the choices provided.\n\nAnswer: A."}, {"branch": 8, "seed": 818018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 13.32925820350647, "model_output": "To approach this question, let's consider the characteristics and common presentations of breast cancer, focusing on the options provided:\n\nA. Nipple retraction: This refers to the inward movement or inversion of the nipple. It can be a sign of an underlying malignancy, particularly if associated with a palpable mass or other concerning features. Nipple retraction can occur due to cancer cells infiltrating the ducts behind the nipple, causing the nipple to retract.\n\nB. Peau d'orange (French for \"skin of the orange\"): This term describes a dimpled, orange peel-like appearance of the skin, usually resulting from lymphedema. While it is associated with breast cancer, especially in the context of inflammatory breast cancer, it's more of a secondary sign indicating advanced disease rather than the most conspicuous initial sign.\n\nC. Puckering: Puckering of the skin is a sign that can be associated with various breast conditions, including fibrocystic changes, benign tumors, or cancer. However, it is not as specific or as commonly associated with breast cancer as some other signs.\n\nD. Cancer en-cuirasse (also known as \"inflammatory breast cancer\"): This is a rare and aggressive form of breast cancer that presents with rapid onset of symptoms, including a red, swollen, and inflamed appearance of the breast, which resembles an inflamed skin condition. While alarming, it represents a specific subtype of cancer rather than a common initial sign of breast cancer in general.\n\nConsidering the above explanations, nipple retraction (A) is often cited as a classic and early sign of breast cancer, especially in the context of breast cancer that originates in the ducts. It is more specific and can be a noticeable change that prompts a patient to seek medical attention, making it the most conspicuous sign among the options listed.\n\nSo, the answer is A."}, {"branch": 9, "seed": 819015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "B", "is_correct": false, "inference_time_sec": 12.973982095718384, "model_output": "To determine the most conspicuous sign in breast cancer, let's evaluate each option:\n\nA. Nipple retraction: This is a common symptom of breast cancer, particularly if it's associated with a palpable mass or a visible change in the direction of the nipple. Nipple retraction can be a result of an underlying tumor pulling the nipple inward. It's often cited as one of the earliest and most noticeable signs of breast cancer, especially in cases of ductal carcinoma in situ (DCIS) or invasive cancer affecting the nipple-areolar complex.\n\nB. Peau d'orange (also known as orange peel skin): This term describes a condition where the skin of the breast looks like the surface of an orange due to the lymphatic vessels being blocked by cancer. It is a significant sign of advanced breast cancer but might not be the first noticeable symptom for many patients.\n\nC. Puckering: Puckering or dimpling of the skin can be a sign of breast cancer, indicating the involvement of the skin by a tumor. However, it is less commonly the first symptom compared to nipple retraction and is more often seen in later stages.\n\nD. Cancer en-cuirasse (also known as \"inflammatory breast cancer\"): This is a rare and aggressive form of breast cancer that presents with redness, swelling, and an orange-peel texture of the skin, resembling an inflammation. It is not typically the most common or conspicuous sign of breast cancer, as it represents an advanced stage of the disease.\n\nConsidering the above explanations, the most conspicuous sign that would prompt a person to seek medical attention and is commonly associated with early detection of breast cancer is nipple retraction. It's a noticeable change that often leads individuals to consult a healthcare provider, making it a critical early warning sign.\n\nAnswer: A."}], "branch_preds": ["A", "A", "A", "A", "A", "A", "A", "A", "A", "A"], "metrics": {"leader": "A", "max_frac": 1.0, "variation_ratio": 0.0, "entropy_bits": 0.0, "valid_n": 10, "none_n": 0, "unanimous": true, "unanim_valid": true, "correct_fraction": 0.0, "leader_correct": false, "class": "unanimous", "wall_time_sec": 131.1663293838501, "mean_branch_time_sec": 13.114289569854737}}
{"index": 8, "picked_index": 9, "id": "6f1fdbc9-920f-4bff-b2eb-ba300fd9cc59", "question": "Which of these findings is not specific of blast injury?", "options": {"A": "Abrasion", "B": "Bruise", "C": "Puncture laceration", "D": "Fracture"}, "gold": "D", "subject_name": "Forensic Medicine", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:54:39.412218+00:00", "branches": [{"branch": 0, "seed": 910042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "D", "is_correct": false, "inference_time_sec": 12.77901554107666, "model_output": "To determine which of the given options is not specific to a blast injury, let's analyze each option in the context of blast trauma:\n\nA. Abrasion: Blast injuries can cause abrasions due to the force of the blast wave stripping away the skin, especially in areas not protected by clothing. This is a common finding in blast injuries.\n\nB. Bruise: Bruising, or ecchymosis, can occur due to the impact of flying debris or the force of the blast wave. The pressure changes associated with a blast can cause blood vessels to rupture, leading to bruising. This is also consistent with blast injuries.\n\nC. Puncture laceration: Puncture lacerations are typically caused by sharp objects, such as shrapnel or debris that penetrates the skin. While shrapnel can be a component of a blast, the term \"puncture laceration\" more specifically implies an entry and exit wound or a wound caused by a sharp object, which is not unique to blast injuries and can be seen in other types of trauma as well.\n\nD. Fracture: Blast injuries can cause fractures due to the high-pressure shock wave generated by the explosion. The force can be transmitted through the body, causing bone fractures. This is a common and specific finding in blast injuries, particularly in the context of primary blast injuries affecting the lungs, gastrointestinal tract, or ears, but also in secondary injuries from flying debris.\n\nConsidering the options, a puncture laceration (C) is the least specific to blast injuries. It can occur from a variety of causes, including but not limited to, blast injuries. The other options, while they can occur in other types of trauma, are more commonly associated with the unique mechanisms of blast injuries.\n\nAnswer: C."}, {"branch": 1, "seed": 911039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "D", "is_correct": true, "inference_time_sec": 10.183429479598999, "model_output": "To determine which of these findings is not specific to a blast injury, let's examine each option in the context of blast injuries:\n\nA. Abrasion: Blast injuries can cause skin abrasions due to the high-pressure shockwave from the blast, which can strip away the superficial layers of the skin. This is a common finding in blast injuries.\n\nB. Bruise: Bruising, or ecchymosis, can also result from the pressure changes and the impact associated with a blast. The shockwave can cause blood vessels to rupture, leading to bruising.\n\nC. Puncture laceration: Puncture wounds from flying debris are a hallmark of blast injuries. The high-velocity objects propelled by the blast can penetrate the skin and underlying tissues, leading to puncture wounds.\n\nD. Fracture: While fractures can be a result of a variety of trauma, including blast injuries, they are not specific to blast injuries. Fractures can occur from blunt trauma, falls, or direct impact in non-blast scenarios. In contrast, the other options (abrasions, bruises, and puncture lacerations) are more directly associated with the unique mechanisms of injury seen in blasts, such as the high-pressure shockwave and flying debris.\n\nTherefore, among the options provided, fractures are the least specific to blast injuries as they can occur in a wide range of traumatic events, not just blasts.\n\nAnswer: D."}, {"branch": 2, "seed": 912036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "D", "is_correct": false, "inference_time_sec": 17.16425371170044, "model_output": "To approach this question, let's consider what is characteristic of blast injuries and the nature of each option provided:\n\n1. **Blast Injuries Overview**: Blast injuries result from the rapid release of energy due to an explosion. This energy release can cause primary, secondary, tertiary, and quaternary effects. Primary blast injuries are due to the shockwave generated by the blast and can affect the air-filled organs, such as the lungs, ears, and gastrointestinal tract. Secondary injuries are from flying debris, tertiary injuries from being thrown by the blast wind, and quaternary injuries encompass all other injuries not classified as primary, secondary, or tertiary.\n\n2. **Analyzing the Options**:\n   - **A. Abrasion**: An abrasion is a superficial wound of the skin, caused by friction or rubbing against a rough surface. While abrasions can occur in various traumatic events, they are not specific to blast injuries. Abrasions can result from a variety of causes, including falls, cuts, or being dragged over a rough surface, and are not typically associated with the shockwave or pressure changes seen in blast injuries.\n   - **B. Bruise (Contusion)**: A bruise results from blood leakage into the tissues from broken capillaries due to trauma. Bruises can occur in the context of blast injuries due to the force exerted on the body, especially if the individual is thrown against an object or the ground.\n   - **C. Puncture Laceration**: Puncture lacerations are typically caused by sharp objects penetrating the skin. While they could be secondary injuries from flying debris in a blast, they are not specific to the primary effects of a blast, which is more about the pressure wave and its effects on the body rather than penetration by external objects.\n   - **D. Fracture**: A fracture is a break in the bone. Fractures can be a result of the force exerted by the blast wave, especially if the force is strong enough to break bones. This is more characteristic of primary blast injuries, where the shockwave can cause bone fractures.\n\n**Conclusion**: Based on the analysis, the finding that is **not specific to blast injuries** is an **abrasion**. Abrasions are more indicative of physical contact with a surface rather than the effects of a shockwave or pressure changes associated with a blast.\n\n**Answer: A.**"}, {"branch": 3, "seed": 913033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "D", "is_correct": false, "inference_time_sec": 11.043428897857666, "model_output": "To determine which of the options is not specific to blast injury, let's consider the characteristics of blast injuries and how each option relates to them:\n\nA. Abrasion: Blast injuries often result in abrasions due to the force of the blast wave causing friction against the skin as the person is propelled or debris hits the skin. Abrasions are a common finding in blast injuries.\n\nB. Bruise: Bruising, or hematoma, can also occur in blast injuries due to the shockwave's impact, which can cause blood vessels to rupture under the skin. Bruises are another common feature of blast trauma.\n\nC. Puncture laceration: Puncture lacerations are more characteristic of penetrating trauma, typically caused by sharp objects, rather than the blast wave itself. In a blast injury, the primary blast wave is responsible for the damage, and it does not usually cause puncture wounds. Puncture wounds are more likely to be caused by flying debris, but the debris typically causes blunt force trauma rather than a clean puncture.\n\nD. Fracture: Fractures can occur in blast injuries due to the shockwave's force, which can cause bones to break. This is a common feature of blast injuries, particularly in the context of high-pressure blasts.\n\nConsidering the mechanisms of injury associated with each option, puncture lacerations (C) are less likely to be directly caused by the blast wave itself and are more characteristic of penetrating trauma, making it the option that is not specific to blast injury.\n\nAnswer: C."}, {"branch": 4, "seed": 914030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "D", "is_correct": false, "inference_time_sec": 15.702243328094482, "model_output": "To determine which of the given options is not specific to blast injury, let's analyze each option in the context of blast injuries:\n\nA. Abrasion: Abrasions are superficial wounds that result from friction or rubbing against a rough surface. While abrasions can occur in various types of injuries, they can also be seen in blast injuries due to flying debris or from being thrown against a surface. However, they are not specific to blast injuries as they can occur in other trauma scenarios.\n\nB. Bruise: A bruise, or contusion, results from blood leakage into the skin and underlying tissues due to trauma. Blast injuries can cause blunt force trauma leading to bruising, especially if the person is thrown or if there's significant pressure wave impact. Bruising is not unique to blast injuries but can occur in other types of trauma.\n\nC. Puncture laceration: Puncture lacerations are deep wounds caused by an object piercing the skin. In the context of a blast injury, flying debris such as shrapnel can cause puncture wounds. This type of injury is indeed more specific to blast injuries due to the nature of the trauma caused by high-velocity projectiles.\n\nD. Fracture: Fractures can result from the high-pressure shockwave generated by a blast, which can cause bones to break. This is a hallmark of blast injuries, especially in cases where the primary blast wave impacts the body directly, leading to fractures without an external wound.\n\nConsidering the options, while abrasions (A) and bruises (B) can be associated with various types of trauma and are not exclusively indicative of blast injuries, puncture lacerations (C) and fractures (D) are more specific to the mechanisms of injury seen in blasts, especially the latter. However, between abrasions and bruises, which are more generally indicative of trauma and not specific to blast injuries, and puncture lacerations, which are more specific due to the nature of blast injuries involving high-velocity debris, the most nonspecific to blast injuries among the options given would be abrasions, as they are the least likely to be directly associated with the unique mechanisms of blast trauma.\n\nAnswer: A."}, {"branch": 5, "seed": 915027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "D", "is_correct": false, "inference_time_sec": 13.872926712036133, "model_output": "To determine which of the listed findings is not specific to a blast injury, let's consider the typical characteristics and mechanisms associated with blast injuries and the nature of each option provided:\n\nA. Abrasion: An abrasion is a superficial wound that results from the removal of the superficial layers of the skin. Blast injuries often involve primary blast injuries, which can cause damage from the overpressure wave. This overpressure can cause skin damage, including abrasions, due to the forceful contact with the ground or debris, making it a possible finding in blast injuries.\n\nB. Bruise (Contusion): A bruise, or contusion, results from blood leakage into the skin and underlying tissues from small blood vessels damaged by trauma. In the context of a blast, the overpressure wave can also cause blunt force trauma, leading to bruising. Thus, bruising can be associated with blast injuries.\n\nC. Puncture laceration: Puncture lacerations are typically caused by a sharp object entering the skin, such as from a sharp piece of metal or glass. While sharp objects can be present in a blast scene, the primary mechanism of injury in a blast is the overpressure wave, which is more likely to cause blunt force injuries rather than penetrating injuries. Puncture lacerations are more characteristic of penetrating trauma rather than the blast overpressure mechanism.\n\nD. Fracture: Fractures can result from the force exerted by the blast overpressure wave, which can be strong enough to cause bone fractures. Blast injuries can also cause secondary injuries from flying debris, which can lead to fractures. Thus, fractures are indeed possible in the context of a blast injury.\n\nConsidering the mechanisms of injury associated with blast trauma, puncture lacerations (C) are not typically caused by the overpressure wave characteristic of a blast but rather by penetrating objects, making it the finding that is not specific to blast injury.\n\nAnswer: C."}, {"branch": 6, "seed": 916024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "D", "is_correct": false, "inference_time_sec": 17.060440063476562, "model_output": "To approach this question, let's consider the characteristics of blast injuries and how they compare to other types of trauma.\n\nBlast injuries are caused by the rapid overpressure and underpressure waves generated by an explosion. These injuries can affect the body in several ways, including:\n\n- **Primary blast injury**: This is due to the direct effect of the pressure wave on the air-filled organs, such as the ears, lungs, and gastrointestinal tract. It can cause injuries such as blast lung injury and middle ear damage.\n- **Secondary blast injury**: This results from the impact of flying debris. It can cause a variety of injuries including lacerations, abrasions, and fractures.\n- **Tertiary blast injury**: This is caused by the body being thrown by the blast wave. It often results in blunt trauma, including fractures and internal injuries.\n\nNow, let's analyze the options given:\n\nA. **Abrasion**: This is a superficial wound caused by the removal of the superficial layers of the skin due to friction. While abrasions can be a result of secondary blast injury from flying debris, they are not specific to blast injuries. They can occur in any situation where the skin is scraped against a rough surface, such as a fall or a vehicle accident.\n\nB. **Bruise**: Bruising, or a contusion, is a result of blood leakage into the tissues from small blood vessels that have been injured. Bruises can occur due to the blunt force trauma associated with blast injuries (tertiary injury) but are not specific to them.\n\nC. **Puncture laceration**: This type of injury involves a break in the skin and underlying tissue caused by an object that enters the body. Puncture wounds can occur from flying debris in a blast, making them specific to the mechanism of injury associated with explosions.\n\nD. **Fracture**: A fracture is a break in a bone. Like puncture wounds, fractures can occur from the impact of flying debris in a blast (secondary injury), and thus, they are specific to the trauma mechanism associated with explosions.\n\nConsidering the above explanations, while all these injuries can occur in the context of a blast, **abrasions (A)** are the least specific to blast injuries because they can be caused by a variety of other mechanisms of trauma, not just the unique dynamics of a blast.\n\nSo, the answer is A."}, {"branch": 7, "seed": 917021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "D", "is_correct": false, "inference_time_sec": 14.832976341247559, "model_output": "To determine which of the given options is not specific to a blast injury, let's analyze each option in the context of blast trauma:\n\nA. Abrasion: An abrasion is a superficial wound that occurs when the skin scrapes against a rough surface, often due to friction. In the context of a blast, abraded areas can occur due to the forceful passage of a blast wave over the skin, causing the skin to scrape against the underlying surface. Thus, abrasions can be seen in blast injuries.\n\nB. Bruise (Contusion): A bruise is a type of injury that occurs when small blood vessels are damaged, causing blood to leak into the surrounding tissues. This can happen in a blast injury due to the shockwave from the blast affecting the capillaries and small blood vessels, leading to bruising. Bruises can be common in blast-related injuries.\n\nC. Puncture laceration: A puncture laceration is typically caused by a sharp object entering the skin, such as a piece of shrapnel. While it's true that shrapnel from a blast can cause puncture wounds, the term \"puncture laceration\" usually suggests an injury from a sharp, pointed object. Blast injuries more commonly result in blunt force injuries rather than sharp object injuries.\n\nD. Fracture: Fractures can occur in blast injuries due to the high-pressure shockwave that can cause bones to break. The force exerted by the blast can be powerful enough to cause structural damage to bones, leading to fractures.\n\nConsidering these explanations, while all the options can be seen in the context of a blast injury, puncture lacerations (option C) are less characteristic of blast injuries compared to the other options, which are more directly associated with the shockwave and pressure effects of a blast. Puncture lacerations are more typically associated with penetrating trauma from shrapnel or other sharp objects, which, although possible in a blast, are not a direct result of the blast wave itself.\n\nSo, the answer is C."}, {"branch": 8, "seed": 918018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "D", "is_correct": false, "inference_time_sec": 12.754230499267578, "model_output": "To determine which of the given options is not specific to a blast injury, let's analyze each option in the context of blast injuries, which are typically caused by the high-pressure shock waves generated by an explosion.\n\nA. Abrasion: An abrasion is a superficial wound caused by the friction or rubbing of the skin against a rough surface. In a blast injury, high-pressure shock waves can cause debris or flying objects to strike the skin, leading to abrasions. Therefore, abrasions can be specific to blast injuries.\n\nB. Bruise (Contusion): A bruise results from blood leakage into the tissues due to blood vessel rupture. Blast injuries can cause blunt force trauma, leading to the rupture of blood vessels and subsequent bruising. Thus, bruising can also be associated with blast injuries.\n\nC. Puncture laceration: A puncture laceration is a wound caused by an object piercing the skin. While it's possible for a piece of debris to cause a puncture wound in a blast, such injuries are not specific to blast injuries and can occur in various traumatic scenarios, including non-explosive incidents.\n\nD. Fracture: Fractures are bone breaks, which can occur due to the high-pressure shock waves from a blast. These waves can directly cause bone damage or indirect damage through flying debris. Fractures are indeed a common finding in blast injuries.\n\nConsidering the options, while all can be associated with trauma, puncture lacerations (C) are not specifically indicative of blast injuries as they can occur from a variety of causes, not just the high-pressure shock waves and flying debris characteristic of blasts. Abrasions, bruises, and fractures are more directly associated with the specific mechanisms of a blast injury.\n\nSo, the answer is C."}, {"branch": 9, "seed": 919015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "D", "is_correct": false, "inference_time_sec": 12.8800630569458, "model_output": "To approach this question, let's consider the characteristics of blast injuries and how they compare to other types of injuries:\n\nA. Abrasion: An abrasion is a superficial wound caused by the friction or rubbing of the skin against a rough surface. In the context of a blast, high-pressure shock waves can cause skin damage, including abrasions, due to the rapid pressure changes and the impact of flying debris. So, abrasions can be a finding in blast injuries.\n\nB. Bruise (Contusion): A bruise is a type of injury that occurs when blood vessels are damaged, leading to blood leakage into the tissues beneath the skin. This can happen due to blunt trauma, which can be caused by the pressure wave generated in a blast. Therefore, bruising can also be a result of a blast injury.\n\nC. Puncture laceration: Puncture wounds are typically caused by a sharp object penetrating the skin. While blast injuries can cause flying debris, the primary mechanism of a blast does not inherently involve the penetration of the skin by a sharp object in the same way that a puncture wound would suggest. Puncture lacerations are more characteristic of direct contact with sharp objects rather than the effects of an explosion's pressure wave.\n\nD. Fracture: Fractures can occur in blast injuries due to the shock waves generated by the explosion, which can cause bones to break. The high-pressure shock wave can also displace the body and cause fractures by throwing the body against objects or by the direct force of the wave itself.\n\nGiven the mechanisms of injury associated with each option, the finding that is least specific to blast injuries is the puncture laceration, as it is more indicative of direct contact with a sharp object rather than the effects of a blast.\n\nAnswer: C."}], "branch_preds": ["C", "D", "A", "C", "A", "C", "A", "C", "C", "C"], "metrics": {"leader": "C", "max_frac": 0.6, "variation_ratio": 0.4, "entropy_bits": 1.295461844238322, "valid_n": 10, "none_n": 0, "unanimous": false, "unanim_valid": false, "correct_fraction": 0.1, "leader_correct": false, "class": "lead50", "wall_time_sec": 138.2960250377655, "mean_branch_time_sec": 13.827300763130188}}
{"index": 9, "picked_index": 10, "id": "3b150083-1a5e-49ef-bc36-41a06b677b32", "question": "Major aim of phase 1 clinical trials is:", "options": {"A": "Safety", "B": "Efficacy", "C": "Dose", "D": "Pharmacokinetics"}, "gold": "C", "subject_name": "Pharmacology", "model": "HPAI-BSC/Llama3.1-Aloe-Beta-8B", "max_new_tokens": 1024, "seed": 42, "timestamp": "2026-01-12T12:57:11.240244+00:00", "branches": [{"branch": 0, "seed": 1010042, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "C", "gold": "C", "is_correct": true, "inference_time_sec": 18.101889848709106, "model_output": "To approach this question, let's break down the phases of clinical trials and the primary objectives of each phase, focusing on Phase 1 trials specifically.\n\n1. **Understanding Clinical Trial Phases:**\n   - **Phase 0:** These are exploratory, first-in-human trials that assess the pharmacokinetics of a drug after a single dose.\n   - **Phase 1:** These trials are the first time a new drug or treatment is given to people and are primarily designed to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in a small group of healthy volunteers or patients.\n   - **Phase 2:** These trials focus on the efficacy and side effects of the drug in a larger group of patients.\n   - **Phase 3:** Large-scale trials that compare the new treatment to commonly used treatments and gather more information on its effects and side effects.\n   - **Phase 4:** Post-marketing surveillance trials designed to detect any rare or long-term adverse effects over a much larger number of patients.\n\n2. **Analyzing the Options:**\n   - **A. Safety:** While safety is indeed a primary concern in Phase 1, it's not the only focus. Safety is a component of Phase 1 but also of all phases of clinical trials.\n   - **B. Efficacy:** Efficacy is primarily assessed in Phase 2 and Phase 3 trials, where the treatment's ability to produce the desired therapeutic effect is evaluated.\n   - **C. Dose:** Finding the optimal dose is a key part of Phase 1 trials, as the initial doses are often much higher than the final therapeutic dose and need to be adjusted to minimize side effects while achieving the desired therapeutic effect.\n   - **D. Pharmacokinetics:** This refers to the study of how the body affects a specific drug after administration, including absorption, distribution, metabolism, and excretion. While pharmacokinetics is indeed studied in Phase 1, the major aim of Phase 1 is more comprehensive, including safety and dose determination.\n\n3. **Conclusion:** Considering the primary objectives of Phase 1 clinical trials, the major aim encompasses not just pharmacokinetics but also safety, dose determination, and, to some extent, the initial assessment of tolerability and pharmacodynamics. However, among the options given, **C. Dose** is the most directly related to the primary aim of Phase 1, as determining the appropriate dose is a critical step in ensuring both safety and efficacy in subsequent phases.\n\n**Answer: C.**"}, {"branch": 1, "seed": 1011039, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "C", "is_correct": false, "inference_time_sec": 14.843232870101929, "model_output": "To approach this question, let's break down the primary objectives of each phase of clinical trials in the context of drug development:\n\n1. **Phase 1 Clinical Trials**: These trials are the first stage of testing in human subjects. The main goals of Phase 1 trials are to assess the safety, tolerability, pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted in the body), and pharmacodynamics (the effects of the drug on the body) of a drug. They are usually conducted with a small number of healthy volunteers or patients.\n\n2. **Safety (Option A)**: While safety is indeed a critical aspect of Phase 1 trials, it's not the only aim. Safety is part of a broader concern for the well-being of participants and includes adverse event monitoring.\n\n3. **Efficacy (Option B)**: Efficacy, or how well the drug works, is primarily assessed in later phases of clinical trials, such as Phase 2 and Phase 3. These phases involve larger populations and are designed to evaluate the effectiveness of the drug for its intended use.\n\n4. **Dose (Option C)**: Determining the appropriate dose is part of the Phase 1 trials, as part of the pharmacokinetics and safety assessments. However, it is not the primary aim of these trials.\n\n5. **Pharmacokinetics (Option D)**: This is indeed one of the major aims of Phase 1 trials, along with safety. Pharmacokinetics helps in understanding how the drug behaves in the body, which is crucial for determining the dosing regimen for future phases of testing.\n\nGiven the options, the most comprehensive and accurate description of the major aim of Phase 1 clinical trials would include both safety and pharmacokinetics, but since the question asks for a single best answer and given that safety is the overarching concern that encompasses the well-being of participants which includes pharmacokinetics, the best answer would focus on safety as the primary aim, with the understanding that it encompasses the other aspects.\n\nSo, the answer is A."}, {"branch": 2, "seed": 1012036, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "C", "is_correct": false, "inference_time_sec": 14.097641706466675, "model_output": "To approach this question, let's break down the objectives of the different phases of clinical trials, focusing on Phase 1:\n\n1. **Understanding Clinical Trial Phases**:\n   - **Phase 1**: The initial phase of testing in human subjects, typically involving a small group of healthy volunteers or patients.\n   - **Phase 2**: Expands to a larger group of patients to assess the efficacy and side effects of the drug.\n   - **Phase 3**: Large-scale studies to confirm efficacy, monitor side effects, compare the new intervention to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.\n   - **Phase 4**: Post-marketing studies to detect any rare or long-term adverse effects over a much larger number of patients.\n\n2. **Objectives of Phase 1 Clinical Trials**:\n   - The primary goal of Phase 1 trials is to assess the safety and tolerability of a new drug, vaccine, or treatment in humans. This includes determining the maximum tolerated dose, identifying side effects, and understanding the pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted in the body) and pharmacodynamics (the effects of the drug on the body).\n   - While efficacy (B) is indeed a critical aspect of later phases, it is not the primary focus of Phase 1.\n   - **Dose (C)** is a part of the assessment but is not the sole aim of Phase 1.\n   - **Pharmacokinetics (D)** is one of the aspects studied in Phase 1, but it is not the major aim; it's more of a method to achieve the primary aim.\n\nGiven these considerations, the major aim of Phase 1 clinical trials is to ensure the safety of the participants, which includes assessing the tolerability and identifying potential side effects, alongside understanding how the drug behaves in the body.\n\n**Answer: A. Safety**"}, {"branch": 3, "seed": 1013033, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "C", "is_correct": false, "inference_time_sec": 13.710979223251343, "model_output": "To determine the major aim of Phase 1 clinical trials, let's break down the phases of clinical trials and their primary objectives:\n\n1. **Phase 1 Clinical Trials**: These are the first stage of testing in human subjects and are primarily designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug or treatment. The main goals include determining a safe dosage range and identifying side effects. While pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted in the body) and pharmacodynamics (the drug's effects on the body) are part of the evaluation, they are not the sole focus. Efficacy, or the degree to which the drug produces the desired therapeutic effect, is not the primary focus of Phase 1 trials but rather of later phases.\n\n2. **Safety (Option A)**: This is the overarching concern in Phase 1 trials. Ensuring the drug is safe for human use, including identifying the maximum tolerated dose and any adverse effects, is the main aim.\n\n3. **Efficacy (Option B)**: This is more relevant to Phase 2 and 3 trials, where the focus shifts from safety to whether the drug is effective in treating the condition it's intended for.\n\n4. **Dose (Option C)**: Determining the dose is part of the safety evaluation but is not the major aim. The dose is a critical component of safety testing.\n\n5. **Pharmacokinetics (Option D)**: While pharmacokinetics is a significant aspect of Phase 1 trials, it is not the major aim. It is one of the methods used to evaluate the safety of the drug.\n\nConsidering these points, the major aim of Phase 1 clinical trials is primarily focused on safety, as it sets the stage for further testing by establishing a safe dose range and understanding potential side effects.\n\nAnswer: A."}, {"branch": 4, "seed": 1014030, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "C", "is_correct": false, "inference_time_sec": 15.595462799072266, "model_output": "To approach this question, let's break down the objectives of the different phases of clinical trials in the process of drug development:\n\n1. **Phase 1 Clinical Trials**: These trials are the first stage of testing in human subjects and are primarily focused on assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug. The main goals are to determine the highest dose of the drug that can be given without causing significant side effects and to understand how the body absorbs, distributes, metabolizes, and excretes the drug (pharmacokinetics).\n\n2. **Phase 2 Clinical Trials**: At this stage, the drug is given to a larger group of people to see if it is effective and to further evaluate its safety. The focus shifts more towards efficacy, looking for side effects and how the drug works.\n\n3. **Phase 3 Clinical Trials**: These trials are conducted on a larger group of patients to confirm the effectiveness of the drug, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug to be used safely.\n\n4. **Phase 4 (Post-marketing surveillance)**: After a drug is approved, these trials are conducted to detect any rare or long-term adverse effects over a much larger patient population.\n\nGiven this information, let's evaluate the options:\n- **A. Safety**: While safety is a critical component of Phase 1, it is not the only aim.\n- **B. Efficacy**: Efficacy is more relevant to later phases of clinical trials.\n- **C. Dose**: Determining the appropriate dose is part of assessing safety and pharmacokinetics in Phase 1.\n- **D. Pharmacokinetics**: This is a key aspect of Phase 1, as it directly involves understanding how the body processes the drug, which is crucial for determining safe dosing and further trial design.\n\nConsidering the above, the most accurate answer that encapsulates the primary aim of Phase 1 clinical trials is the assessment of pharmacokinetics, alongside safety, but since the question asks for a singular major aim, pharmacokinetics is the most precise choice provided.\n\nAnswer: D."}, {"branch": 5, "seed": 1015027, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "C", "is_correct": false, "inference_time_sec": 17.687772512435913, "model_output": "To approach this question, let's break down the phases of clinical trials and the primary objectives of each phase, focusing on Phase 1:\n\n1. **Phase 1 Clinical Trials**: These are the first stage of testing in human subjects and are primarily conducted to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug or treatment. The main goal is to determine a safe dosage range and identify side effects.\n\n2. **Safety (Option A)**: While safety is a crucial aspect of Phase 1 trials, it's not the only aim. Safety is closely related to and intertwined with other objectives but is not the sole focus.\n\n3. **Efficacy (Option B)**: Efficacy is more closely related to the later phases of clinical trials, particularly Phase 2 and Phase 3. These phases aim to evaluate whether the drug works in people who have a certain disease or condition, in addition to its safety.\n\n4. **Dose (Option C)**: Determining the optimal dose is indeed a part of Phase 1 trials, but saying it's the \"major aim\" might be too narrow. The dose is determined as part of the broader assessment of safety and pharmacokinetics.\n\n5. **Pharmacokinetics (Option D)**: This is the study of how a drug is absorbed, distributed, metabolized, and excreted in the body. It is a key component of Phase 1 trials, as understanding these processes is critical to determining the safety and efficacy of a drug. In fact, pharmacokinetics is a major aspect of the safety evaluation in Phase 1.\n\nConsidering the above explanations, the most comprehensive and accurate answer to the question is that the major aim of Phase 1 clinical trials is to assess the safety, which includes pharmacokinetics, among other factors. However, since the options are structured to require a single best answer and given that pharmacokinetics is a critical part of safety assessment in Phase 1, it could be argued that pharmacokinetics is a key component of the safety assessment. But in clinical trial parlance, the primary aim is more broadly safety.\n\nSo, the best answer, while acknowledging the nuances, would be aligned with the broadest and most inclusive aim of Phase 1 trials, which is safety, but since the format demands a single best answer and given the emphasis on the detailed study of drug behavior in the body:\n\n**Answer: A. Safety**"}, {"branch": 6, "seed": 1016024, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "C", "is_correct": false, "inference_time_sec": 13.906818151473999, "model_output": "To answer this question, let's break down the phases of clinical trials and the primary objectives of each:\n\n1. **Phase 1 Clinical Trials**: These are the first stage of testing in human subjects for a new drug or treatment. The primary goal of Phase 1 trials is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug. These trials typically involve a small group of healthy volunteers or patients with the disease the drug is intended to treat.\n\n2. **Safety (A)**: While safety is a major concern in all phases of clinical trials, it is especially critical in Phase 1 trials. The main focus here is to identify any adverse effects or toxicities associated with the drug at different doses, ensuring the safety of participants.\n\n3. **Efficacy (B)**: Efficacy is the primary focus of later phases of clinical trials (Phase 2 and 3). In these phases, the drug is tested in larger groups to confirm its effectiveness and compare it to commonly used treatments.\n\n4. **Dose (C)**: Determining the optimal dose is indeed part of Phase 1, but it is not the major aim. The aim is more comprehensive, including not just finding the right dose but also how the drug is absorbed, distributed, metabolized, and excreted (pharmacokinetics) and its effects on the body (pharmacodynamics).\n\n5. **Pharmacokinetics (D)**: This is also a critical aspect of Phase 1 trials, involving the study of how the drug is absorbed, distributed, metabolized, and excreted in the body. However, it is part of a broader objective rather than the major aim.\n\nConsidering these points, the major aim of Phase 1 clinical trials is primarily focused on assessing the safety of the drug, ensuring it is safe for further testing in larger populations.\n\nSo, the answer is A."}, {"branch": 7, "seed": 1017021, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "C", "is_correct": false, "inference_time_sec": 13.160778999328613, "model_output": "To determine the major aim of phase 1 clinical trials, let's break down the phases of clinical trials and the focus of each:\n\n1. **Phase 1 Clinical Trials**: These are the first stage of testing in human subjects and are primarily designed to assess the safety and tolerability of a new drug or treatment. The main objectives include determining the maximum tolerated dose, identifying side effects, and understanding the pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted in the body). However, safety is the overarching goal, as it is crucial to ensure that the drug does not pose unacceptable risks to the participants before moving to larger, efficacy-focused trials.\n\n2. **Efficacy** (Option B) is the primary focus of later stages of clinical trials (Phase 2 and 3), where the new intervention is tested to see if it is effective in treating the condition it's intended for.\n\n3. **Dose** (Option C) is indeed a part of what is determined in Phase 1, as the aim is to find the highest dose that can be given without causing unacceptable side effects. However, it's a component of the broader goal of assessing safety and pharmacokinetics rather than the major aim itself.\n\n4. **Pharmacokinetics** (Option D) is also a key area of investigation in Phase 1 trials. It is the study of how a drug is absorbed, distributed, metabolized, and excreted by the body. While crucial, it is a part of the broader safety and dose determination process rather than the primary aim.\n\nGiven this analysis, the major aim of Phase 1 clinical trials is to assess the safety of a new drug or treatment, making Option A, **Safety**, the correct answer.\n\nSo, the final answer is A."}, {"branch": 8, "seed": 1018018, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "A", "gold": "C", "is_correct": false, "inference_time_sec": 15.493343591690063, "model_output": "To approach this question, let's break down the objectives of the different phases of clinical trials, focusing on Phase 1:\n\n1. **Phase 1 Clinical Trials**: These are the first stage of testing in human subjects and are primarily focused on assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug. The primary goal is to determine a safe dosage range and identify side effects.\n\n2. **Safety (Option A)**: While safety is indeed a critical aspect of Phase 1 trials, it is not the only focus. The trials are designed to evaluate how the drug is absorbed, distributed, metabolized, and excreted by the body, as well as its safety profile.\n\n3. **Efficacy (Option B)**: Efficacy, which refers to how well the drug works, is the primary focus of later stages of clinical trials, particularly Phase 2 and 3. These phases aim to determine whether the drug is effective for its intended use.\n\n4. **Dose (Option C)**: Determining the appropriate dose is part of the objectives of Phase 1 trials, but it's not the major aim. The goal is not just to find the dose but to understand the safety and pharmacokinetics at various doses.\n\n5. **Pharmacokinetics (Option D)**: This refers to how the body affects a specific drug after administration, encompassing aspects like absorption, distribution, metabolism, and excretion (ADME). While pharmacokinetics is a key component of Phase 1 trials, the trials aim to cover more than just pharmacokinetics, including safety and the determination of an appropriate dose.\n\nConsidering the above explanations, the major aim of Phase 1 clinical trials is not just one of these aspects but a combination of them, with a strong emphasis on safety, pharmacokinetics, and dose determination. However, given the options provided and the necessity to choose the best answer, **safety** is the overarching concern because without safety, the other aspects cannot be adequately assessed. Safety is the foundation upon which efficacy and other aspects are evaluated in subsequent phases.\n\nSo, the answer is A."}, {"branch": 9, "seed": 1019015, "temperature": 0.8, "top_p": 0.8, "top_k": 50, "pred": "D", "gold": "C", "is_correct": false, "inference_time_sec": 15.189780235290527, "model_output": "To approach this question, let's break down the phases of clinical trials and the primary objectives of each phase:\n\n1. **Phase 1 Clinical Trials**: These are the first stage of testing in human subjects and are primarily designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug or treatment. The main focus is on determining the highest dose that can be given without causing significant side effects, as well as how the drug is absorbed, distributed, metabolized, and excreted by the body (pharmacokinetics).\n\n2. **Safety (A)**: While safety is a critical component of Phase 1 trials, it is not the only aim. Safety is assessed in the context of dose escalation, side effects, and overall tolerability, but it is part of a broader set of objectives.\n\n3. **Efficacy (B)**: Efficacy is typically assessed in later phases of clinical trials (Phase 2 and 3). Phase 2 trials start to evaluate whether the drug works in people who have a certain disease or condition, and Phase 3 trials confirm its efficacy and monitor side effects in a larger population.\n\n4. **Dose (C)**: Determining the optimal dose is indeed a key part of Phase 1 trials. The goal is to find the maximum tolerated dose (MTD) or the dose that produces the desired effect without unacceptable side effects. However, this is a means to an end, rather than the end itself.\n\n5. **Pharmacokinetics (D)**: This is the correct answer. Pharmacokinetics (PK) studies in Phase 1 trials measure how the body affects the drug, including how it is absorbed, distributed, metabolized, and excreted. Understanding PK is crucial for determining the appropriate dosing regimen and for the design of subsequent phases of the drug development process.\n\nIn summary, while safety and dose are important aspects of Phase 1 trials, the major aim of these trials is to understand the pharmacokinetics of the drug, along with its safety profile and tolerability.\n\nAnswer: D."}], "branch_preds": ["C", "A", "A", "A", "D", "A", "A", "A", "A", "D"], "metrics": {"leader": "A", "max_frac": 0.7, "variation_ratio": 0.30000000000000004, "entropy_bits": 1.1567796494470395, "valid_n": 10, "none_n": 0, "unanimous": false, "unanim_valid": false, "correct_fraction": 0.1, "leader_correct": false, "class": "lead50", "wall_time_sec": 151.81161379814148, "mean_branch_time_sec": 15.178769993782044}}
